

RESEARCH ARTICLE

Astrocytic deletion of protein kinase R-like ER kinase (PERK) does not affect learning and memory in aged mice but worsens outcome from experimental stroke

Anirudhya Lahiri¹  | James C. Walton² | Ning Zhang² | Neil Billington³ |
A. Courtney DeVries^{2,4,5,6,7} | Gordon P. Meares^{1,2,4}

¹Department of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, West Virginia, USA

²Department of Neuroscience, West Virginia University, Morgantown, West Virginia, USA

³Department of Biochemistry, West Virginia University, Morgantown, West Virginia, USA

⁴Rockefeller Neuroscience Institute, West Virginia University, Morgantown, West Virginia, USA

⁵Department of Medicine, Division of Hematology and Oncology, West Virginia University, Morgantown, West Virginia, USA

⁶WVU Cancer Institute, Morgantown, West Virginia, USA

⁷West Virginia Clinical and Translational Science Institute, West Virginia University, Morgantown, West Virginia, USA

Correspondence

Gordon P. Meares, Department of Microbiology, Immunology and Cell Biology, Department of Neuroscience, West Virginia University, 64 Medical Center Drive, HSC North 2084, Morgantown, WV, USA.
Email: gmeares@hsc.wvu.edu

Funding information

National Institute of General Medical Sciences; National Institute of Neurological Disorders and Stroke

Abstract

Aging is associated with cognitive decline and is the main risk factor for a myriad of conditions including neurodegeneration and stroke. Concomitant with aging is the progressive accumulation of misfolded proteins and loss of proteostasis. Accumulation of misfolded proteins in the endoplasmic reticulum (ER) leads to ER stress and activation of the unfolded protein response (UPR). The UPR is mediated, in part, by the eukaryotic initiation factor 2 α (eIF2 α) kinase protein kinase R-like ER kinase (PERK). Phosphorylation of eIF2 α reduces protein translation as an adaptive mechanism but this also opposes synaptic plasticity. PERK, and other eIF2 α kinases, have been widely studied in neurons where they modulate both cognitive function and response to injury. The impact of astrocytic PERK signaling in cognitive processes was previously unknown. To examine this, we deleted PERK from astrocytes (AstroPERK^{KO}) and examined the impact on cognitive functions in middle-aged and old mice of both sexes. Additionally, we tested the outcome following experimental stroke using the transient middle cerebral artery occlusion (MCAO) model. Tests of short-term and long-term learning and memory as well as of cognitive flexibility in middle-aged and old mice

Abbreviations: AstroPERK^{KO}, Astrocyte-specific PERK knockout; ATF4, activating transcription factor 4; ATF6, activating transcription factor 6; CHOP, C/EBP homologous protein; CNS, central nervous system; Cre, cyclization recombinase; eIF2 α , eukaryotic initiation factor 2 α ; ER, endoplasmic reticulum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GCN2, general control nonderepressible 2; GFAP, glial fibrillary acidic protein; GLAST, glutamate-aspartate transporter; HRI, heme-regulated inhibitor; IRE1, inositol requiring enzyme 1; ISRIB, integrated stress response inhibitor; MCAO, middle cerebral artery occlusion; MWM, Morris water maze; NE, northeast quadrant; Nrf2, nuclear factor erythroid 2-related factor 2; NW, northwest quadrant; P-eIF2 α , phospho-eIF2 α ; PERK, protein kinase R-like ER kinase; PKR, protein kinase R; PTQ, previous target quadrant; SE, southeast quadrant; SW, southwest quadrant; TQ, target quadrant; UPR, unfolded protein response; XBP1, X-box binding protein 1.

Edited by Junie Paula Warrington and Huaye Zhang. Reviewed by Wensheng Lin.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2023 The Authors. *Journal of Neuroscience Research* published by Wiley Periodicals LLC.



revealed that astrocytic PERK does not regulate these processes. Following MCAO, AstroPERK^{KO} had increased morbidity and mortality. Collectively, our data demonstrate that astrocytic PERK has limited impact on cognitive function and has a more prominent role in the response to neural injury.

KEYWORDS

aging, astrocytes, glia, learning and memory, MCAO, protein kinase R-like ER kinase (PERK), RRID:AB_10692650, RRID:AB_2095847, RRID:AB_2096481, RRID:AB_2107445, RRID:AB_2631098, RRID:AB_304334, RRID:Addgene_28306, RRID:IMSR_JAX:023066, RRID:IMSR_JAX:024098, RRID:nif-0000-00280, RRID:SCR_002798, RRID:SCR_014210, RRID:SCR_014289, stroke, unfolded protein response

1 | INTRODUCTION

Aging is associated with cognitive decline (Deary et al., 2009) and is the main risk factor for neurodegeneration and stroke (GBD 2016 Neurology Collaborators, 2019; Wyss-Coray, 2016). With age, cells accumulate damage, mutations, and gradually decline in the maintenance of protein homeostasis (proteostasis) (López-Otín et al., 2013). The loss of proteostasis is associated with age-related cognitive decline (Cabral-Miranda et al., 2020; Martínez et al., 2017) and neurodegeneration (Hetz & Mollereau, 2014; Labbadia & Morimoto, 2015; Martínez et al., 2017). The mechanisms ensuring proteostasis are numerous and involve molecular chaperones, transcription factors, and organelle-specific sensors that monitor protein disturbances (Labbadia & Morimoto, 2015).

The endoplasmic reticulum (ER) is a vital organelle within this proteostasis network (Braakman & Bulleid, 2011). The ER is essential for synthesis, folding, and processing of secretory and transmembrane proteins (Schwarz & Blower, 2016). Diverse pathological insults lead to the accumulation of misfolded proteins within the ER, which subsequently results in ER stress (Sprenkle et al., 2017). To restore homeostasis, cells initiate the evolutionarily conserved unfolded protein response (UPR) (Walter & Ron, 2011). The UPR is orchestrated by three trans-ER membrane proteins, PKR (protein kinase R)-like ER kinase (PERK), inositol requiring enzyme (IRE) 1, and activating transcription factor (ATF) 6, each of which mediate distinct downstream signaling pathways with substantial crosstalk among them (Brewer, 2014). The activation of the UPR ultimately allows cells to cope with increased protein folding load (Ron & Walter, 2007; Walter & Ron, 2011). However, chronic UPR activation in response to unresolved ER stress can lead to aberrant nonresolving inflammation and results in cell death (Walter & Ron, 2011; Zhang & Kaufman, 2008). The UPR is partly orchestrated by the trans-ER membrane Ser/Thr protein kinase PERK which, after sensing misfolded protein accumulation in the ER lumen, is activated by dimerization and autophosphorylation (Harding et al., 1999; Liu et al., 2000). Activated PERK phosphorylates the eukaryotic initiation factor 2 α (eIF2 α), which in turn leads to global attenuation of protein translation while simultaneously increasing expression of selected proteins including ER resident molecular chaperones in order to restore proteostasis (Harding et al., 1999, 2003; Walter & Ron, 2011). This ER monitoring network

Significance

Neuronal PERK signaling is a vital regulator of cognitive function. In this study, we have examined the contribution of astrocytic PERK signaling in learning and memory. Our results indicate that astrocytic PERK does not influence short-term or long-term memory in aged mice. The results support the notion that PERK-dependent regulation of learning and memory is likely cell intrinsic to neurons. Additionally, we have also demonstrated that astrocytic PERK signaling is critical to limiting detrimental outcome and death from experimental stroke.

is perturbed during aging (Martínez et al., 2017). ER resident chaperones and UPR signaling molecules in CNS have been reported to decrease in old rodents compared to young (Paz Gavilán et al., 2006) and the responsiveness of IRE1 is also diminished (Cabral-Miranda et al., 2020), suggesting their reduced function may contribute to age-related disease. PERK has been widely studied in neurodegeneration and injury. Neural injury, such as ischemic stroke, leads to suppression of protein synthesis through PERK-dependent phosphorylation of eIF2 α at serine 51 (Althausen et al., 2001; Cooper et al., 1977; Kleihues et al., 1975; Kumar et al., 2001; Mengesdorf et al., 2002; Owen et al., 2005; Sanderson et al., 2010). Recently it was shown that PERK deletion from neurons worsens middle cerebral artery occlusion (MCAO)-induced infarct volume and behavioral deficits, indicating a functional role in outcome following injury (Wang et al., 2020). Collectively, many studies have demonstrated that PERK signaling has a functional role in neural injury and disease. These same pathways are also important in learning and memory (Costa-Mattioli et al., 2009). In neurons, eIF2 α has emerged as a convergence point of proteostasis and cognition (Trinh & Klann, 2013).

Memory formation requires synaptic plasticity, which is the activity-dependent changes of neuronal synaptic transmission (Citri & Malenka, 2008). In addition, new protein translation at the preexisting synapses is particularly necessary for memory formation (Costa-Mattioli et al., 2009; Klann & Sweatt, 2008). As such, the phosphorylation of eIF2 α impedes memory formation



(Costa-Mattoli et al., 2007, 2009). Consistent with this, ER stress and PERK activation have been causally implicated in memory impairment in rodents (Lin et al., 2018; Ma et al., 2013; Ounallah-Saad et al., 2014; Sen et al., 2017; Sidrauski et al., 2013; Zhu et al., 2016). Moreover, targeting the PERK pathway by either genetic or pharmacological approaches has been reported to ameliorate neuronal loss and memory impairment in various neurodegenerative and neural injury models (Chou et al., 2017; Devi & Ohno, 2014; Halliday et al., 2015; Ma et al., 2013; Moreno et al., 2013; Radford et al., 2015; Sen et al., 2017). Importantly, physiological phosphorylation of eIF2 α allows cognitive flexibility and disruption of p-eIF2 α or the downstream transcription factor ATF4 impairs this process (Oliveira & Klann, 2022; Trinh et al., 2012). Currently, it is unknown if the PERK-dependent regulation of cognitive function is exclusive to neurons or if glial cells, such as astrocytes, also influence this process.

Astrocytes are a major glial cell type, which orchestrate diverse critical functions in the central nervous system such as formation and function of synapses, providing trophic support to neurons, development of white and gray matter, blood flow regulation, driving neuroinflammation, and promoting CNS repair after neurological insult (Sofroniew, 2009; Sofroniew & Vinters, 2010). Astrocytes regulate synaptic transmission by forming the “tripartite synapse” (Sofroniew & Vinters, 2010). Moreover, astrocytes by virtue of producing various neuroactive compounds, can modulate synaptic plasticity (Ota et al., 2013) which makes them an ideal candidate for the regulation of complex brain functions such as learning and memory (Adamsky & Goshen, 2018). Indeed, previous studies have shown that astrocytes are critical in learning and memory (Adamsky & Goshen, 2018; Ben Menachem-Zidon et al., 2011; Han et al., 2012; Stehberg et al., 2012; Suzuki et al., 2011).

The functional role of astrocytic PERK in the context of learning and memory has not been studied previously. Here, we deleted PERK from astrocytes and examined the impact on cognitive function and cerebral ischemia in aged mice. Our data showed that PERK deletion from astrocytes does not worsen age-related cognitive decline but does result in greater morbidity and mortality following experimental stroke.

2 | MATERIALS AND METHODS

2.1 | Animals

PERK^{fl/fl} (“Control”: Jackson Laboratories) (RRID:IMSR_JAX:023066) (Zhang et al., 2002) and astrocyte selective Cre-recombinase expressing (GFAP-Cre, line 77.6) (RRID:IMSR_JAX:024098) (Gregorian et al., 2009) mice were purchased, subsequently housed and bred under the care of the Office of Lab Animal Resources at West Virginia University. All animal studies were conducted with approval from the WVU institutional animal care and use committee and in accordance with the guide for the Care and Use of Laboratory Animals. Female GFAP-Cre mice were crossed with male PERK^{fl/fl}

mice and progeny F1 heterozygous females with GFAP-Cre were backcrossed with male PERK^{fl/fl} mice to obtain the astrocytic PERK knockout (“AstroPERK^{KO}”; GFAP-Cre, PERK^{fl/fl}) mice. The Cre allele was always maintained as hemizygous. Mice were on a 12/12 h light/dark cycle with food and water ad libitum. Tail biopsies were taken from 17–21-day-old animals and genomic DNA was isolated using Wizard SV genomic DNA purification system (Promega). Genotyping was done by standard polymerase chain reaction (PCR) using platinum II hot start green PCR master mix (Invitrogen). Subsequently, genotype was determined by agarose gel electrophoresis. The genotyping primers (Integrated DNA Technologies) are used to detect the presence of Cre-recombinase allele (forward primer: GCT AAC CAT GTT CAT GCC TTC; reverse primer: AGG CAA ATT TTG GTG TAC GG) and PERK floxed allele (forward primer: TTG CAC TCT GGC TTT CAC TC; reverse primer: AGG AGG AAG GTG GAA TTT GG).

2.2 | Open field test

All behavioral tests were conducted by an experimenter blinded to the genotypes of the mice. General locomotor activity was measured using an open field apparatus that was an acrylic rectangular box without a lid [dimensions: 40.64 cm (length) \times 40.64 cm (width) \times 38.1 cm (height); San Diego Instruments PAS-Open Field System PAS004634] containing photocells. Data were collected by photo beam disruption due to animal movement (16 photo beams in both x and y axis directions for locomotor activity and 16 elevated photo beams in z axis for rearing activity) and analyzed by PAS system software. The center area was defined as an inner section 7.62 cm away from each of the walls. Ambulation, rearing activity, center, and peripheral activity measured by counting the number of photo beam interruptions using PAS-Open field software. Each mouse was placed at the center of the apparatus and was allowed to move freely within. Data were collected for 30 min.

2.3 | Y-maze test

Spontaneous alternation Y-maze test was performed to assess short-term spatial working memory as described previously (Priour & Jadavji, 2019) with minor modifications. The Y-shaped maze made of gray polycarbonate [dimensions: 38 cm (length) \times 8 cm (width) \times 10 cm (height)] was surrounded by black colored maze cues on the walls of the room. Each mouse was placed in one arm of the maze and allowed to roam freely inside the maze for 8.5 min. All trials were video recorded and analyzed by ANY-maze video tracking software (Stoelting) (RRID:SCR_014289). Entry to an arm was recorded only when all of the animal's limbs were within that particular arm. Percent spontaneous alternation was calculated as follows: the number of triads containing entries into three arms/maximum possible alternations (total number of arms entered-2) \times 100.



2.4 | Morris water maze test

Morris water maze test was performed as described previously (Vorhees & Williams, 2006) with minor modifications in the protocol. A circular pool (1.07 m in diameter) was filled with water and nontoxic paint was used to make the water opaque. A circular platform (diameter: 10 cm) was submerged below the water surface. The location of the hidden platform was constant throughout the training phase. The water maze was surrounded by black colored maze cues on the walls of the room. Briefly, mice were trained for seven consecutive days [four trials/day/mouse from each direction (north, south, east, and west) in a random order] to find hidden platform in a circular water pool. Maximum duration for each trial was 60 s and the trial ended when a mouse found the hidden platform successfully. Once mice found the platform, they were allowed to sit on the platform for 15 s and then returned to a heated drying cage. Mice that did not find the platform within the trial period were guided to the platform, and then were allowed to sit there for 15 s before returning to the cage. The probe trial was administered at the 7th day right after the last training session. During the probe trial, the platform was removed from the maze and mice were allowed to swim for 60 s after which they were returned to the heated cage. To assess cognitive flexibility, mice underwent reversal test where mice were retrained for two consecutive days as described above to learn a new platform location. At the end of last training session on day 2, another probe trial (reversal probe trial) was administered as described before. Each trial was video recorded and analyzed by ANY-maze video tracking software (Stoelting) (RRID:SCR_014289).

2.5 | Primary astrocyte culture

Primary astrocytes were prepared from postnatal day 0–1 control (PERK^{fl/fl}) and AstroPERK^{KO} (GFAP-Cre, PERK^{fl/fl}) mice as previously described (Meares et al., 2012). In brief, pups were euthanized by decapitation, and the brains were collected into cold media. Meninges, cerebellum, and olfactory bulbs were removed and cerebra were collected. Tissue was disrupted by trituration and filtered through a 100 μ m cell strainer. Cells were centrifuged at 300g for 5 min, resuspended in fresh astrocyte medium (Dulbecco's Modified Eagle Medium [DMEM]) with 10% fetal bovine serum (FBS) (Corning), 16 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic acid (HEPES) (Gibco), 1X nonessential amino acids (Corning), 2 mM L-glutamine (Sigma-Aldrich), 100 units/mL penicillin (Gibco), 100 μ g/mL streptomycin (Gibco), and 50 μ g/mL gentamicin (Sigma-Aldrich), and transferred onto T-75 tissue culture flasks. The cultures were maintained for approximately 12–14 days at 37°C in humidified 5% CO₂/95% air atmosphere. One half of the media was changed every 3–4 days. Astrocytes were separated from microglia by shaking at 200 rpm for 2 h. Subsequently, media in the flask was removed and astrocytes were incubated with trypsin (Gibco) for 5 min at 37°C. Cells were collected in media and centrifuged for 5 min at 300g.

Thereafter, astrocytes were seeded in six-well plates and 48–72 h later cells were collected for protein.

2.6 | Western blotting

Primary astrocytes were washed twice with 1X Dulbecco's phosphate-buffered saline (DPBS) (Gibco) and lysed with immunoprecipitation (IP) lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.5% NP-40, and 1X phosphatase/protease inhibitor cocktail (Thermo scientific). Fifteen-month-old (mean age = 462.4 days) control and AstroPERK^{KO} mice were anesthetized using isoflurane (Vet one). Following cessation of breathing, mice were transcardially perfused with 30 mL ice cold 1X DPBS (Gibco). Brains were removed and cortex and hippocampus fractions were isolated. Tissues were disrupted by trituration and filtered through a 100 μ m cell strainer. Cells were centrifuged at 300g for 5 min, resuspended in IP lysis buffer. The lysates were subsequently centrifuged for 15 min at 17,000g at 4°C and clear supernatants were taken for further analysis. Protein concentrations were determined using the bicinchoninic acid assay (BCA) (Thermo Scientific). Equal amounts of protein from each sample were solubilized in Laemmli sample buffer [2% Sodium Dodecyl Sulfate (SDS)] and heated for 5 min at 95°C. Proteins were separated by 8% or 10% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked in 5% milk in wash buffer (20 mM Tris base, 137 mM NaCl and 0.05% Tween-20 (TBST)) followed by an overnight incubation at 4°C with primary antibody diluted in 5% bovine serum albumin (BSA) (Fisher) or milk, according to the manufacturer's recommendation. Primary antibodies were diluted as follows; PERK 1:2000 (Cell signaling, 3192S), P-eIF2 α 1:2000 (Cell signaling, 3398S), eIF2 α 1:3000 (Cell signaling, 5324S), GLAST 1:2000 (Abcam, ab416), GFAP 1:3000 (Cell signaling, 12389S), and GAPDH 1:12000 (Sigma-Aldrich, MAB374). Antibody used are listed in Table 1. Membranes were washed for 1 h with frequent changes to TBST. Membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit or goat anti-mouse (1:3000 dilution, Jackson Immuno Research) secondary antibody diluted in 5% milk in TBST for 1 h at room temperature. Membranes were again washed for 1 h and TBST was changed frequently. Proteins were detected by enhanced chemiluminescence (Thermo Scientific). Immunoblots were imaged on an ChemiDoc Touch imaging system (Bio-Rad) and quantified using Image Lab software (Bio-Rad) (RRID:SCR_014210).

2.7 | Reverse transcription (RT)-PCR

RNA was isolated using 1 mL of TRIzol (Life technologies) according to the manufacturer's protocol. RNA was quantified using a NanoDrop system (Thermo scientific). For cDNA synthesis, 1 μ g of RNA was mixed with oligo dT primer and incubated at 70°C for 5 min followed immediately by 5 min on ice. A mix containing reaction buffer (Promega), moloney murine leukemia virus reverse



TABLE 1 List of antibodies used in the study.

Antibody name	Structure of the immunogen against which the animal was immunized	The manufacturer, catalog or lot number, RRID, species it was raised in, monoclonal or polyclonal	Concentration used
PERK	A synthetic peptide corresponding to residues surrounding Val248 of human PERK protein	(Cell Signaling Technology Cat# 3192, RRID:AB_2095847) Rabbit Monoclonal	1:2000
P-eIF2 α	A synthetic phosphopeptide corresponding to residues surrounding Ser51 of human eIF2 α	Cell signaling 3398S RRID:AB_2096481 Rabbit Monoclonal	1:2000
Total eIF2 α	A purified recombinant protein fragment representing sequence in the central region of human eIF2 α	(Cell Signaling Technology Cat# 5324, RRID:AB_10692650) Rabbit Monoclonal	1:3000
GFAP	A synthetic peptide corresponding to residues surrounding Asp395 of human GFAP protein.	(Cell Signaling Technology Cat# 12389, RRID:AB_2631098) Rabbit Monoclonal	1:3000
GLAST	Synthetic peptide corresponding to Rat EAAT1 (C-terminal). Corresponding to 20 residues from the C-terminal	Abcam ab416 RRID:AB_304334 Rabbit Polyclonal	1:2000
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase from rabbit muscle	(Millipore Cat# MAB374, RRID:AB_2107445) Mouse Monoclonal	1:12000

transcriptase (Promega), deoxynucleotide triphosphates (dNTPs) (Promega), and ribonuclease inhibitor (Promega) was added and incubated at 42°C for 1 h. The reaction was terminated by incubation at 95°C for 5 min. Subsequently, cDNA was used as input DNA for PCR (using platinum II hot start green PCR master mix (Invitrogen)) to detect the presence of Cre-recombinase (forward primer: GCT AAC CAT GTT CAT GCC TTC; reverse primer: AGG CAA ATT TTG GTG TAC GG). Cre presence was confirmed by running PCR products on agarose gel.

2.8 | Retro-orbital injection of adeno-associated virus (AAV)

Premade AAV viral stock was purchased from Addgene. pAAV-FLEX-tdTomato was a gift from Edward Boyden (Addgene viral prep # 28306-PHPeB) ([RRID:Addgene_28306](#)). Mice were anesthetized briefly with isoflurane. Gentle pressure was applied to the skin dorsal and ventral to the eye so that the eye partially protrudes. The needle (27 gauge) of the syringe was placed in the medial canthus to access the retro-orbital sinus. An injection volume of 150 μ L containing 5×10^{11} viral genomes (vg) was used. Mice were analyzed 3–4 weeks postinjection.

2.9 | Microscopy

Following euthanasia, mice were transcardially perfused with 30 mL of cold DPBS (Gibco) followed by 30 mL of cold 4% paraformaldehyde (PFA). Brains were removed and postfixed in 4% PFA overnight.

Brains were then washed with PBS and immersed in 20% then 30% sucrose, incubating at 4°C until the tissue sinks at each step. Brains were then frozen and sectioned at 25 μ m on a cryostat (Leica). Sections were placed on glass slides and mounted using ProLong glass antifade mountant with NucBlue (ThermoFisher). Slides were then imaged on a slide scanner (Olympus) and subsequently imaged on a Nikon A1R confocal microscope.

For H&E staining, coronal sections of formalin-fixed paraffin embedded brain were used. Slides were evaluated by a pathologist blinded to the experimental groups. Microscopic changes were graded as to severity utilizing the International Harmonization of Nomenclature and Diagnostic (INHAND) standards. Histopathology was conducted by iHisto inc.

2.10 | Immunostaining

Following TTC staining, tissue was fixed in 10% formalin overnight then paraffin embedded. Immunostaining was conducted in a blinded fashion by iHisto inc. Tissues were sectioned, dewaxed, and stained using anti-CHOP (ThermoFisher, MA1-250) and anti-GFAP (Cell Signaling, #3670). Immunostaining was enhanced using Tyramide Signal Amplification. Slides were imaged using a slide scanner at 20 \times magnification. Quantification was conducted by selecting semi-random fields based on GFAP staining in the deep cortex and the caudate putamen, using the corpus callosum as a reference landmark. Cells were quantified from the ipsilateral and contralateral hemispheres from three animals of each genotype with a minimum of 300 cells per hemisphere were counted. Total cell number, based on DAPI staining, was determined in an



automated fashion using Photoshop. GFAP and CHOP positive cells were then counted manually from the same field. To assess astrocyte number, branching degree, and Feret diameter, images were analyzed with Cell Profiler V4 (www.cellprofiler.org, RRID:nif-0000-00280) (Stirling et al., 2021). A custom pipeline was developed for this analysis. The mean measurements from each animal were used for statistical assessment.

2.11 | Middle cerebral artery occlusion (MCAO)

MCAO surgeries were conducted as described previously (Hattori et al., 2000), with minor modifications. Briefly, mice were anesthetized with isoflurane and an incision in the skin made to visualize the proximal common carotid artery. A small incision was made in the vessel and then a sterile monofilament (occluder) threaded into the internal carotid artery to a point that prevents blood flow into the right middle cerebral artery. The occluder remained in place for 60 min and then was removed. Surgeries were performed by a researcher blinded to the genotypes. Neuroscores were assessed based on the following scale: 0—no deficit, 1—forelimb weakness and/or turning to one side when suspended by tail, 2—circling, 3—unable to bear weight or falling to the affected side, and 4—lack of spontaneous movement or barrel rolling (Liu, Johnson, et al., 2019; Longa et al., 1989).

2.12 | Statistical analysis

All statistical analyses were performed using GraphPad Prism (version 9) (RRID:SCR_002798) software. Unpaired two-tailed *t*-test or Mann–Whitney test was used to compare between two groups. Ordinary two-way ANOVA test was used to compare between repeatedly measured datasets. Sidak's multiple comparison test was used for post-hoc analysis. Ordinary two-way ANOVA test was performed to determine interactions between genotype and sex, genotype and age as well as age and sex. Tukey's multiple comparison test was used for post-hoc analysis. Three-way ANOVA was performed to examine interactions between genotype, age, and sex. Tukey's multiple comparison test was performed for post-hoc analysis. Statistical significance is defined as $p < .05$. Data are represented as Mean \pm SD on all bar charts. For the violin plots, dark spaced line on the top, middle, and bottom of a violin represents 75th percentile, median, and 25th percentile of the dataset, respectively. Statistical tests are listed in Table 2.

3 | RESULTS

3.1 | Deletion of PERK in astrocytes

To examine the impact of astrocytic PERK in learning and memory, we generated conditional knockout mice by crossing PERK^{fl/fl} with GFAP-Cre (AstroPERK^{KO}). To validate the astrocyte-selective Cre, we

retro-orbitally injected both control (PERK^{fl/fl}) and AstroPERK^{KO} mice with adeno-associated virus (PHP.eB serotype) carrying a flex-switch controlled, Cre-inducible tdTomato (Chan et al., 2017). As shown in Figure 1a,b, Cre expressing mice show widespread tdTomato labeling of astrocytes, as determined by the complex and bushy cell morphology. No tdTomato expression was observed in Cre negative animals. To confirm PERK knockout in astrocytes, we isolated and cultured primary astrocytes from the control and AstroPERK^{KO} mice. As shown in Figure 1c, PERK is markedly reduced in Cre-expressing astrocytes. The levels of PERK, phospho-eIF2 α (P-eIF2 α), the astrocytic glutamate transporter GLAST, and GFAP were immunoblotted from the cortex and hippocampus. As shown in Figure 1d–g, PERK expression was not reduced in the cortex and hippocampus fraction of AstroPERK^{KO} animals, suggesting PERK expression is low in astrocytes, which is consistent with previously reported single-cell sequencing data (Saunders et al., 2018). Furthermore, expression of P-eIF2 α also remained unchanged between the genotypes in both brain regions. GFAP and GLAST expression were also similar in both genotypes. Taken together, these data demonstrate that PERK is effectively deleted from GFAP-expressing astrocytes without causing obvious alterations in cellular phenotype.

3.2 | Astrocytic PERK ablation does not affect general locomotion

To assess the behavioral effects of astrocytic PERK deletion, we first tested general locomotor activity using open field test in age- and sex-matched middle-aged (12 months; mean age: 349.9 days) (Figure 2a–c) and old (18 months; mean age: 527.2 days) (Figure 2d–f) mice (Table 3). We first analyzed the dataset to detect sex-specific effects and found none. Therefore, we combined males and females together for further downstream analysis. We found no difference in total ambulation (Figure 2a) and total rearing (Figure 2b) between control and AstroPERK^{KO} mice for middle-aged as well as old (Figure 2d,e) mice. Rodents typically show distinct aversions to large, brightly lit, open and unknown environments and typically reside near the periphery of the open field chamber (Choleris et al., 2001). Consistent with this behavior, both control and AstroPERK^{KO} mice mostly occupied the periphery and showed no difference between genotypes in the center activity for middle-aged (Figure 2c) and old (Figure 2f) mice, respectively. Additionally, we did not observe any age-specific effect on total ambulation, total rearing, and center activity (Table 3) in our animals. Overall, these data indicate that PERK deletion from GFAP+ astrocytes does not affect general locomotor functions.

3.3 | Astrocytic PERK deletion does not alter spatial working memory

Genetic ablation of PERK in neurons impairs short-term spatial working memory (Zhu et al., 2016). We hypothesized that long-term

TABLE 2 Summary of statistics for each figure.

Figure	Test parameter	Who versus who	N	Is data distribution normal? (Shapiro-Wilk test)	Test name	p value	F (DFn, DFd)	Post-hoc analysis
1E	Cortex PERK/GAPDH Western blot densitometry	Control versus AstroPERK ^{KO}	Control = 5 (M = 4; F = 1) AstroPERK ^{KO} = 5 (M = 3; F = 2)	No	Mann-Whitney test	.9524	N/A	N/A
1E	Cortex P-eIF2 α /Total eIF2 α Western blot densitometry	Control versus AstroPERK ^{KO}	Control = 5 (M = 4; F = 1) AstroPERK ^{KO} = 5 (M = 3; F = 2)	Yes	Unpaired two-tailed t-test	.3917	N/A	N/A
1E	Cortex GFAP/GAPDH Western blot densitometry	Control versus AstroPERK ^{KO}	Control = 5 (M = 4; F = 1) AstroPERK ^{KO} = 5 (M = 3; F = 2)	Yes	Unpaired two-tailed t-test	.1446	N/A	N/A
1E	Cortex GLAST/GAPDH Western blot densitometry	Control versus AstroPERK ^{KO}	Control = 5 (M = 4; F = 1) AstroPERK ^{KO} = 5 (M = 3; F = 2)	Yes	Unpaired two-tailed t-test	.9723	N/A	N/A
1G	Hippocampus PERK/GAPDH Western blot densitometry	Control versus AstroPERK ^{KO}	Control = 5 (M = 4; F = 1) AstroPERK ^{KO} = 5 (M = 3; F = 2)	Yes	Unpaired two-tailed t-test	.8589	N/A	N/A
1G	Hippocampus P-eIF2 α /Total eIF2 α Western blot densitometry	Control versus AstroPERK ^{KO}	Control = 5 (M = 4; F = 1) AstroPERK ^{KO} = 5 (M = 3; F = 2)	Yes	Unpaired two-tailed t-test	.6128	N/A	N/A
1G	Hippocampus GFAP/GAPDH Western blot densitometry	Control versus AstroPERK ^{KO}	Control = 5 (M = 4; F = 1) AstroPERK ^{KO} = 5 (M = 3; F = 2)	Yes	Unpaired two-tailed t-test	.8941	N/A	N/A
1G	Hippocampus GLAST/GAPDH Western blot densitometry	Control versus AstroPERK ^{KO}	Control = 5 (M = 4; F = 1) AstroPERK ^{KO} = 5 (M = 3; F = 2)	Yes	Unpaired two-tailed t-test	.4582	N/A	N/A
2A	Total Ambulation (open field test)	Middle-aged (12 months) Control versus AstroPERK ^{KO}	Control = 17 (M = 7; F = 10) AstroPERK ^{KO} = 17 (M = 8; F = 9)	No	Mann-Whitney test	.1309	N/A	N/A
2B	Total Rearing (open field test)	Middle-aged (12 months) Control versus AstroPERK ^{KO}	Control = 17 (M = 7; F = 10) AstroPERK ^{KO} = 17 (M = 8; F = 9)	No	Mann-Whitney test	.3986	N/A	N/A
2C	% Center Tendency (open field test)	Middle-aged (12 months) Control versus AstroPERK ^{KO}	Control = 17 (M = 7; F = 10) AstroPERK ^{KO} = 17 (M = 8; F = 9)	Yes	Unpaired two-tailed t-test	.0944	N/A	N/A
2D	Total Ambulation (open field test)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 8 (M = 3; F = 5) AstroPERK ^{KO} = 9 (M = 5; F = 4)	No	Mann-Whitney test	.4234	N/A	N/A
2E	Total Rearing (open field test)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 8 (M = 3; F = 5) AstroPERK ^{KO} = 9 (M = 5; F = 4)	Yes	Unpaired two-tailed t-test	.6264	N/A	N/A
2F	% Center Tendency (open field test)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 8 (M = 3; F = 5) AstroPERK ^{KO} = 9 (M = 5; F = 4)	Yes	Unpaired two-tailed t-test	.5894	N/A	N/A
2G	No of Arm Entries (Y-maze test)	Middle-aged (12 months) Control versus AstroPERK ^{KO}	Control = 17 (M = 7; F = 10) AstroPERK ^{KO} = 17 (M = 8; F = 9)	Yes	Unpaired two-tailed t-test	.9079	N/A	N/A
2H	% Spontaneous Alternation (Y-maze test)	Middle-aged (12 months) Control versus AstroPERK ^{KO}	Control = 17 (M = 7; F = 10) AstroPERK ^{KO} = 17 (M = 8; F = 9)	Yes	Unpaired two-tailed t-test	.0999	N/A	N/A
2I	No Of Arm Entries (Y-maze test)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 8 (M = 3; F = 5) AstroPERK ^{KO} = 9 (M = 5; F = 4)	Yes	Unpaired two-tailed t-test	.8176	N/A	N/A
2J	% Spontaneous Alternation (Y-maze test)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 8 (M = 3; F = 5) AstroPERK ^{KO} = 9 (M = 5; F = 4)	Yes	Unpaired two-tailed t-test	.2216	N/A	N/A



TABLE 2 (Continued)

Figure	Test parameter	Who versus who	N	Is data distribution normal? (Shapiro-Wilk test)	Test name	p value	F (DFn, DFd)	Post-hoc analysis
3A	Latency To Platform Entry (Morris water maze, Training phase)	Middle-aged (12 months) Control versus AstroPERK ^{KO}	Control = 15 (M = 6; F = 9) AstroPERK ^{KO} = 14 (M = 5; F = 9)	N/A	Ordinary two-way ANOVA	.3633	F (1, 167) = 0.8310	Sidak's multiple comparisons test
3B	% Time In Quadrants (Morris water maze, Probe Trial)	Middle-aged (12 months) Control versus AstroPERK ^{KO}	Control = 15 (M = 6; F = 9) AstroPERK ^{KO} = 14 (M = 5; F = 9)	N/A	Ordinary two-way ANOVA	.9943	F (1, 108) = 5.129e-005	Sidak's multiple comparisons test
3C	Time Spent In Platform Area (Morris water maze, Probe Trial)	Middle-aged (12 months) Control versus AstroPERK ^{KO}	Control = 15 (M = 6; F = 9) AstroPERK ^{KO} = 14 (M = 5; F = 9)	No	Mann-Whitney test	.1546	N/A	N/A
3D	Latency To Platform Entry (Morris water maze, Reversal training phase)	Middle-aged (12 months) Control versus AstroPERK ^{KO}	Control = 15 (M = 6; F = 9) AstroPERK ^{KO} = 14 (M = 5; F = 9)	N/A	Ordinary two-way ANOVA	.1940	F (1, 54) = 1.729	Sidak's multiple comparisons test
3E	% Time In Quadrants (Morris water maze, Reversal Probe Trial)	Middle-aged (12 months) Control versus AstroPERK ^{KO}	Control = 15 (M = 6; F = 9) AstroPERK ^{KO} = 14 (M = 5; F = 9)	N/A	Ordinary two-way ANOVA	.9965	F (1, 108) = 1.976e-005	Sidak's multiple comparisons test
3F	Time Spent In Platform Area (Morris water maze, Reversal Probe Trial)	Middle-aged (12 months) Control versus AstroPERK ^{KO}	Control = 15 (M = 6; F = 9) AstroPERK ^{KO} = 14 (M = 5; F = 9)	No	Mann-Whitney test	.1088	N/A	N/A
4A	Latency To Platform Entry (Morris water maze, Training phase)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 8 (M = 3; F = 5) AstroPERK ^{KO} = 9 (M = 5; F = 4)	N/A	Ordinary two-way ANOVA	.0685	F (1, 105) = 3.388	Sidak's multiple comparisons test
4B	% Time In Quadrants (Morris water maze, Probe Trial)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 8 (M = 3; F = 5) AstroPERK ^{KO} = 9 (M = 5; F = 4)	N/A	Ordinary two-way ANOVA	.9884	F (1, 60) = 0.0002127	Sidak's multiple comparisons test
4C	Time Spent In Platform Area (Morris water maze, Probe Trial)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 8 (M = 3; F = 5) AstroPERK ^{KO} = 9 (M = 5; F = 4)	Yes	Unpaired two-tailed t-test	.0845	N/A	N/A
4D	Latency To Platform Entry (Morris water maze, Reversal training phase)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 8 (M = 3; F = 5) AstroPERK ^{KO} = 9 (M = 5; F = 4)	N/A	Ordinary two-way ANOVA	.7721	F (1, 30) = 0.08542	Sidak's multiple comparisons test
4E	% Time In Quadrants (Morris water maze, Reversal Probe Trial)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 8 (M = 3; F = 5) AstroPERK ^{KO} = 9 (M = 5; F = 4)	N/A	Ordinary two-way ANOVA	.6896	F (1, 60) = 0.1610	Sidak's multiple comparisons test
4F	Time Spent In Platform Area (Morris water maze, Reversal Probe Trial)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 8 (M = 3; F = 5) AstroPERK ^{KO} = 9 (M = 5; F = 4)	Yes	Unpaired two-tailed t-test	.5011	N/A	N/A
5A	Neuroscore (24h post-MCAO)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 11 (M = 6; F = 5) AstroPERK ^{KO} = 13 (M = 9; F = 4)	Yes	Unpaired two-tailed t-test	.0007	N/A	N/A
5B	Total Ambulation (open field test post-MCAO)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 10 (M = 5; F = 5) AstroPERK ^{KO} = 7 (M = 5; F = 2)	Yes	Unpaired two-tailed t-test	.0476	N/A	N/A

(Continues)

TABLE 2 (Continued)

Figure	Test parameter	Who versus who	N	Is data distribution normal? (Shapiro-Wilk test)	Test name	p value	F (DFn, DFd)	Post-hoc analysis
5C	Total Rearing (open field test post-MCAO)	Old (18 months) Control versus AstroPERK ^{KO}	Control = 10 (M = 5; F = 5) AstroPERK ^{KO} = 7 (M = 5; F = 2)	Yes	Unpaired two-tailed t-test	.0397	N/A	N/A
5D	% Survival (post-MCAO)	Old (18 months) Control versus AstroPERK ^{KO}	N/A	N/A	Log-rank (Mantel-Cox) test	.0475	N/A	N/A
6B	% of CHOP + cells in GFAP + cells Immunofluorescence	Old (18 months) Control versus AstroPERK ^{KO} Contralateral hemisphere versus Ipsilateral hemisphere	Control = 3 AstroPERK ^{KO} = 3	N/A	Ordinary two-way ANOVA	.0033	F (1, 8) = 17.01	Tukey's multiple comparisons test
6B	% of CHOP positive cells in GFAP-cells (post-MCAO) Immunofluorescence	Old (18 months) Control versus AstroPERK ^{KO} Contralateral hemisphere versus Ipsilateral hemisphere	Control = 3 AstroPERK ^{KO} = 3	N/A	Ordinary two-way ANOVA	.7250	F (1, 8) = 0.1328	Tukey's multiple comparisons test
7A	Astrocytes per field (post-MCAO) Immunofluorescence	Old (18 months) Control versus AstroPERK ^{KO} Contralateral hemisphere versus Ipsilateral hemisphere	Control = 3 AstroPERK ^{KO} = 3	N/A	Ordinary two-way ANOVA	.7133	F (1, 8) = 0.1450	Tukey's multiple comparisons test
7B	Branching Degree (post-MCAO) Immunofluorescence	Old (18 months) Control versus AstroPERK ^{KO} Contralateral hemisphere versus Ipsilateral hemisphere	Control = 3 AstroPERK ^{KO} = 3	N/A	Ordinary two-way ANOVA	.8165	F (1, 8) = 0.05753	Tukey's multiple comparisons test
7D	Feret Diameter (post-MCAO) Immunofluorescence	Old (18 months) Control versus AstroPERK ^{KO} Contralateral hemisphere versus Ipsilateral hemisphere	Control = 3 AstroPERK ^{KO} = 3	N/A	Ordinary two-way ANOVA	.9889	F (1, 8) = 0.0002043	Tukey's multiple comparisons test
Supplementary 1A	% Time In Target Quadrant (Probe Trial Morris Water Maze)	Middle-aged (12 months) Control versus Old (18 months)	Middle aged = 29 (Control: M = 6, F = 9; AstroPERK ^{KO} : M = 5, F = 9) Old = 17 (Control: M = 3, F = 5; AstroPERK ^{KO} : M = 5; F = 4)	No	Mann-Whitney test	.0099	N/A	N/A
Supplementary 1B	Time Spent In Platform Area (Morris water maze, Probe Trial)	Middle-aged (12 months) Control versus Old (18 months)	Middle aged = 29 (Control: M = 6, F = 9; AstroPERK ^{KO} : M = 5, F = 9) Old = 17 (Control: M = 3, F = 5; AstroPERK ^{KO} : M = 5; F = 4)	Yes	Unpaired two-tailed t-test	.0065	N/A	N/A
Supplementary 1C	No of Platform Line Crossing (Morris water maze, Probe Trial)	Middle-aged (12 months) Control versus Old (18 months)	Middle aged = 29 (Control: M = 6, F = 9; AstroPERK ^{KO} : M = 5, F = 9) Old = 17 (Control: M = 3, F = 5; AstroPERK ^{KO} : M = 5; F = 4)	Yes	Unpaired two-tailed t-test	.0453	N/A	N/A



TABLE 2 (Continued)

Figure	Test parameter	Who versus who	N	Is data distribution normal? (Shapiro-Wilk test)	Test name	p value	F (DFn, DFd)	Post-hoc analysis
Supplementary 1D	% Time In Target Quadrant (Reversal Probe Trial) Morris Water Maze	Middle-aged (12 months) Control versus Old (18 months)	Middle aged =29 (Control: M=6, F=9; AstroPERK ^{KO} : M=5, F=9) Old =17 (Control: M=3, F=5; AstroPERK ^{KO} : M=5; F=4)	Yes	Unpaired two-tailed t-test	.2123	N/A	N/A
Supplementary 1E	Time Spent In Platform Area (Morris water maze, Reversal Probe Trial)	Middle-aged (12 months) Control versus Old (18 months)	Middle aged =29 (Control: M=6, F=9; AstroPERK ^{KO} : M=5, F=9) Old =17 (Control: M=3, F=5; AstroPERK ^{KO} : M=5; F=4)	No	Mann-Whitney test	.7478	N/A	N/A
Supplementary 1F	No of Platform Line Crossing (Morris water maze, Reversal Probe Trial)	Middle-aged (12 months) Control versus Old (18 months)	Middle aged =29 (Control: M=6, F=9; AstroPERK ^{KO} : M=5, F=9) Old =17 (Control: M=3, F=5; AstroPERK ^{KO} : M=5; F=4)	No	Mann-Whitney test	.8508	N/A	N/A

deletion of PERK from astrocytes would diminish support for neurons and impair memory. To test this, we performed Y-maze spontaneous alternation test to examine short-term working memory in control and AstroPERK^{KO} mice. As before, there were no sex-specific effects and therefore we combined males and females for subsequent analysis. Our data demonstrated that there were no differences in total arm entries (Figure 2g,i) or spontaneous alternation rate (Figure 2h,j) between control and AstroPERK^{KO} mice of both age groups. Typically, young mice exhibit an alternation rate of approximately 70% and alternation rates decline progressively as animals age (Li et al., 2020). In accordance with previous studies, both middle-aged (12 months) and old (18 months) mice displayed an average spontaneous alternation rate of below 50% suggesting age-related impairment that is not worsened by PERK deletion. However, there was no age-specific effect in the Y-maze performance (Table 4). Taken together, these data suggest that astrocytic PERK does not regulate short-term spatial working memory.

3.4 | Astrocytic PERK ablation does not alter long-term memory and cognitive flexibility in middle-aged mice

PERK inhibition by genetic and pharmacological means improves memory consolidation (Ounallah-Saad et al., 2014) and hippocampal-dependent learning and memory (Sharma et al., 2018) in rodents. Moreover, PERK inhibition has been reported to improve spatial memory following traumatic brain injury (Sen et al., 2017) and in an Alzheimer's disease model (Ma et al., 2013). Therefore, we examined whether the AstroPERK^{KO} mice have differences in long-term spatial memory at middle age (12 months). As before, there were no sex-specific effects and therefore we combined males and females for subsequent analysis. In the training phase, mice learned the location of the hidden platform, as shown by a decrease in the latency to platform entry ($p < .0001$; ordinary two-way ANOVA). There were no significant differences in the learning ability between control and AstroPERK^{KO} mice (Figure 3a). After the last training session, we conducted probe trial (Figure 3b,c). Both the control and AstroPERK^{KO} mice spent significantly more time in the target quadrant (TQ) (two-way ANOVA, Sidak's multiple comparison test) that contained the platform during the training phase compared to other quadrants (Figure 3b). There were no significant differences in time spent in target quadrant (Figure 3b) and time spent in the platform area (Figure 3c) between control and AstroPERK^{KO} mice. Both control and AstroPERK^{KO} mice employed a similar strategy to find the platform during the probe trial, which was quantified by the parameter path efficiency to first platform entry (Table 5).

Genetic ablation of PERK from forebrain neurons leads to impairment of cognitive flexibility (Trinh et al., 2012; Zhu et al., 2016). To examine the effect of astrocytic PERK ablation in cognitive flexibility, we conducted reversal probe trial. During the reversal training phase, control and AstroPERK^{KO} mice learned the new platform location ($p < .0001$; ordinary two-way ANOVA) equally well (Figure 3d).




FIGURE 1 Deletion of PERK from GFAP-expressing astrocytes. (a) AstroPERK^{KO} (GFAP-Cre, PERK^{fl/fl}) mice (left) and Cre negative PERK^{fl/fl} (right) mice were retro-orbitally injected with 5×10^{11} viral genomes of the Cre-inducible pAAV-FLEX-tdTomato (PHP.eB serotype). Three weeks postinjection, tdTomato expression was evaluated as an indicator of Cre activity. Scale bar = 1 mm. (b) Higher magnification showing tdTomato expressing cells display astrocyte morphology. Scale bar = 50 μ m. (c) Primary astrocytes were isolated from PERK^{fl/fl} mice without or with GFAP-Cre followed by immunoblotting for PERK and GAPDH. Cortex (d, e) and hippocampus (f, g) were isolated from 15-month-old control (PERK^{fl/fl}) and AstroPERK^{KO} mice. Levels of PERK, P-eIF2 α , eIF2 α , GLAST, GFAP, and GAPDH are measured by immunoblotting and quantified from the cortex (d, e) and hippocampus (f, g). Cre expression is confirmed by RT-PCR. Data are represented as means \pm SD. Each point represents an individual animal (blue dot = male, orange dot = female). Numerical *p* values are shown.




FIGURE 2 Legend on next page

FIGURE 2 PERK deletion in astrocytes does not alter general locomotion and short-term working memory. (a–c) Middle-aged (12 months) control, AstroPERK^{KO} ($n = 17$ for each genotype) and (d, e) old (18 months) control ($n = 8$), AstroPERK^{KO} ($n = 9$) mice underwent open field test. Total ambulation, total rearing, and percent center activity between two genotypes for middle-aged (a–c) and old (d–f) mice are plotted, respectively. (g, h) Middle-aged and (i, j) old control and AstroPERK^{KO} mice underwent Y-maze spontaneous alternation test. Total number of arm entries and spontaneous alternation rate are plotted for (g, h) middle-aged and (i, j) old mice, respectively. Each point represents an individual animal (blue dot = male, orange dot = female). Numerical p values are shown.

In the reversal probe trial, control mice spent significantly more time in new target quadrant than the previous target quadrant (PTQ; quadrant which contained platform during the probe trial) ($p = .0087$, control TQ vs. control PTQ, two-way ANOVA with Tukey's multiple comparison test) (Figure 3e). However, AstroPERK^{KO} mice spent comparable amount of time in both target quadrant and previous target quadrant ($p = .9998$, AstroPERK^{KO} TQ vs. AstroPERK^{KO} PTQ, two-way ANOVA with Tukey's multiple comparison test) (Figure 3e) which indicates that AstroPERK^{KO} mice were less efficient in learning the new platform location compared to control. However, there was no significant difference between AstroPERK^{KO} and control mice in the time spent in the target quadrant or the previous target quadrant (Figure 3e). Additionally, control and AstroPERK^{KO} mice spent comparable amount of time in the platform area (Figure 3f). Overall, our results demonstrate that astrocytic PERK ablation does not alter long-term spatial memory but may suggest a subtle difference in cognitive flexibility in middle-aged mice.

3.5 | Astrocytic PERK ablation does not alter long-term memory and cognitive flexibility in old mice

We next examined long-term memory and cognitive flexibility in old (18 months) mice to determine if astrocytic PERK deletion would alter age-related cognitive impairment. As before, there were no sex-specific effects and therefore we combined males and females for subsequent analysis. During the training phase, both the control and AstroPERK^{KO} mice learned the platform location. (Figure 4a) ($p = .0002$, ordinary two-way ANOVA). Consistent with the middle-aged mice, there were no significant differences in time spent in target quadrant (Figure 4b) or platform area (Figure 4c) between control and AstroPERK^{KO} mice during the probe trial. Both control and AstroPERK^{KO} mice employed a similar strategy to find the platform during the probe trial, which was quantified by the parameter path efficiency to first platform entry (Table 6). Overall, our data suggest that like the middle-aged cohort, PERK deletion from astrocytes does not affect long-term spatial memory in old mice.

To examine the cognitive flexibility in old mice, reversal probe trial was conducted. During the reversal training phase, both control and AstroPERK^{KO} mice learned the platform location equally well (Figure 4d) ($p = .0376$; ordinary two-way ANOVA). During the reversal probe trial, both control and AstroPERK^{KO} mice spent a comparable amount of time in the target quadrant and the previous target quadrant, indicating they did not effectively extinguish the previously learned location (Figure 4e). Additionally, both genotypes spent a similar amount of time in the platform area (Figure 4f).

We next analyzed the data using age as the only independent variable. Expectedly, middle-aged mice performed significantly better in water maze test compared to old mice (Figure S1a–c). During the probe trial, middle-aged mice spent significantly more time in target quadrant and platform area as well as performed more platform line crossings (Figure S1a–c) which indicates superior long-term memory. Taken together, our data demonstrate that middle-aged mice have superior long-term memory compared to old mice. However, during the reversal probe trial, both middle-aged and old mice spent comparable amount of time in target quadrant and platform area (Figure S1d–f). Additionally, there was no significant difference in the number of platform line crossing between the middle-aged and old mice (Figure S1f). Our data are consistent with previous reports that described similar age-related cognitive decline in rodents (Kennard & Woodruff-Pak, 2011; van Praag et al., 2005). Collectively, these data suggest that PERK deletion from astrocytes does not worsen age-related cognitive impairment.

3.6 | Deletion of PERK from astrocytes worsens experimental stroke outcome in aged mice

Our initial hypothesis that long-term PERK deletion from astrocytes would impair cognitive function was not supported by the data. Therefore, we next tested if PERK deletion would affect outcome following an ER stress-inducing injury. For this, we used the experimental ischemic stroke model of middle cerebral artery occlusion (MCAO). This model has been reliably shown to induce ER stress and PERK activation (Li et al., 2019; Morimoto et al., 2007; Owen et al., 2005; Rissanen et al., 2006; Sanderson et al., 2010; Wang et al., 2020). Additionally, PERK deletion from neurons resulted in greater functional impairment following MCAO (Wang et al., 2020). Using the same cohort of mice as in Figure 4 (plus 3–4 test-naïve mice per genotype to ensure prior behavioral testing would not affect outcome) these mice underwent 60 min transient MCAO. Mice were assessed at 24 h post-MCAO and impairment scored. The AstroPERK^{KO} mice were significantly more impaired 24 h after MCAO (Figure 5a). The mice were further assessed at 72 h post-MCAO by general locomotor activity. Again, the AstroPERK^{KO} showed more impairment with less activity in the open field and less rearing activity (Figure 5b,c). Consistent with worse outcome, AstroPERK^{KO} had significantly higher mortality following MCAO (Figure 5d). To confirm ER stress and PERK activation in astrocytes following MCAO, tissue sections were stained for CHOP and GFAP. As shown in Figure 6a, control animals had robust CHOP staining in the ipsilateral side in both GFAP positive astrocytes and GFAP



TABLE 3 Open field test.

Age	12 months						18 months					
	Control			AstroPERK ^{KO}			Control			AstroPERK ^{KO}		
	Genotype	Sex	N	Genotype	Sex	N	Genotype	Sex	N	Genotype	Sex	N
Total beam break	Control	M	7	AstroPERK ^{KO}	M	8	Control	M	3	AstroPERK ^{KO}	M	5
	Control	F	10	AstroPERK ^{KO}	F	9	Control	F	5	AstroPERK ^{KO}	F	4
Total ambulation	3510 ± 229.2			3718.5 ± 187.94			4161.33 ± 400.03			3811 ± 365.62		
Total rearing	2821.43 ± 223.9			3172.25 ± 171.59			2550.4 ± 209.87			3056.8 ± 358.39		
% Center activity	330.14 ± 20.23			205 ± 64.27			260.8 ± 19.13			384 ± 35.5		
	25.99 ± 3.13			28.12 ± 2.29			31.43 ± 2.63			31.59 ± 3.08		

Note: Middle-aged (12 months) and old (18 months) control and AstroPERK^{KO} mice underwent open field test. Composite data from the tests are depicted in the table. Data are represented as Mean ± SEM. Abbreviations: AstroPERK^{KO}, Astrocyte-specific PERK knockout mice; F, female; M, male.

negative cells. The AstroPERK^{KO} mice also had CHOP expression in the ipsilateral side but were largely restricted to GFAP negative cells. The percentage of CHOP positive astrocytes following MCAO was selectively and significantly reduced in the AstroPERK^{KO} animals (Figure 6b). These data confirm PERK activation in astrocytes following MCAO. The infarct caused by the MCAO was variable and did not correlate with functional outcome (Figure S2). The apparent lack of difference in infarction between the genotypes is likely due to significantly more of the AstroPERK^{KO} dying before collection for TTC staining preventing detection of potentially larger infarcts in the knockout animals. Histopathological evaluation from animals that survived to 72h showed neuronal necrosis, edema, and neuropil vacuolation, as expected. No pathology was noted in the contralateral hemispheres of the control or AstroPERK^{KO} mice, indicating that PERK deletion does not affect normal CNS development or architecture (Figure S3). Collectively, these data show that life-long deletion of PERK from astrocytes leads to worse outcome and increased risk of death from experimental stroke.

We next examined if PERK deletion impacts astrocyte numbers or morphology in the uninjured or injured tissue. The number of astrocytes was similar between control and AstroPERK^{KO} (Figure 7a). Morphology was examined based on GFAP staining. The branching degree (number of terminal branches/branches originating from the soma) was quantified and showed that PERK deletion did not impact the complexity of the cytoskeleton (Figure 7b,c). Additionally, we assessed astrocyte size based on Feret's diameter of GFAP staining and found that PERK deletion did not significantly impact size (Figure 7d,e). These data show that PERK does not regulate astrocyte number or morphology following ischemic injury. The data from the uninjured contralateral tissue also suggest that PERK deletion does not impact astrocyte development nor lead to astrocyte loss or overt morphological defects in the healthy CNS.

4 | DISCUSSION

The relationship between protein synthesis and long-term memory has been known for more than 50 years as protein synthesis inhibitors were found to impair long-term memory in mammals (Glassman, 1969). Phosphorylation of the α subunit of eukaryotic initiation factor 2 (eIF2 α) has been described as a focal point for the control of translation initiation (Krishnamoorthy et al., 2001; Ron & Harding, 2000). This phosphorylation occurs at serine 51 and is mediated in a stimulus-dependent fashion by four kinases: PERK, protein kinase R (PKR), general control nonderepressible (GCN) 2, and heme-regulated inhibitor (HRI) (Costa-Mattioli & Walter, 2020). Further studies have established a role of eIF2 α phosphorylation in regulation of learning and long-term spatial memory in rodents (Costa-Mattioli et al., 2005, 2007; Di Prisco et al., 2014). As a result, eIF2 α kinases, including PERK, are central regulators of cognitive function (Trinh & Klann, 2013). Physiologically, the phosphorylation of eIF2 α serves as a rheostat that properly limits memory formation, allowing for behavioral flexibility (Oliveira & Klann, 2022). However,



TABLE 4 Y-maze test.

Age	12 months				18 months			
	Control		AstroPERK ^{KO}		Control		AstroPERK ^{KO}	
Genotype	M	F	M	F	M	F	M	F
Sex	M	F	M	F	M	F	M	F
N	7	10	8	9	3	5	5	4
Number of arm entries	50.71 ± 3.12	52.7 ± 3.32	43.88 ± 3.21	59.89 ± 3.67	50.67 ± 4.28	47.20 ± 3.23	48.20 ± 5.02	46.25 ± 1.95
% Spontaneous alternation	27.23 ± 2.57	37.93 ± 2.01	37.12 ± 4.07	40.88 ± 2.79	43.47 ± 4.03	37.79 ± 4.15	41.10 ± 2.67	50.48 ± 2.62

Note: Middle-aged (12 months) and old (18 months) control and AstroPERK^{KO} mice underwent Y-maze spontaneous alternation test. Composite data from the tests are depicted in the table. Data are represented as Mean ± SEM.

Abbreviations: AstroPERK^{KO}, Astrocyte-specific PERK knockout mice; F, female; M, male.

in various neurodegenerative diseases, chronic PERK activation and subsequent eIF2 α phosphorylation in CNS is observed (Scheper & Hoozemans, 2015). As a result, translation of key synaptic proteins is suppressed and may contribute to cognitive decline (Halliday et al., 2017; Moreno et al., 2012, 2013; Oliveira et al., 2021). These previous studies have clearly defined PERK signaling in control of protein translation as a regulator of cognitive function. However, previous studies have focused on examining the contribution of neuronal PERK signaling in cognitive function. Therefore, an important question remains: does PERK signaling in glia also contribute to learning and memory?

To begin to answer this question, we deleted PERK in astrocytes. From our immunofluorescent and histological analyses, we can infer that PERK deletion from astrocytes did not impact the gross morphology and structure of the CNS or the normal development and survival of astrocytes. We hypothesized that loss of PERK, which is a central regulator of proteostasis, would in the long-term diminish astrocyte support of neurons and manifest as cognitive impairment. Aging is associated with progressive proteostasis impairment in various model organisms as well as in humans (Brehme et al., 2014; Hipp et al., 2019; Taylor, 2016). Therefore, we subjected middle-aged (12 months) and old (18 months) cohorts of control and AstroPERK^{KO} mice to a battery of behavioral tests to assess cognitive function. We found that PERK deletion from astrocytes did not impair general locomotor function, which is consistent with findings from global pharmacological inhibition of PERK (Sen et al., 2020). Moreover, astrocytic PERK ablation did not affect learning and memory in either age cohort. This may suggest that the effects of PERK signaling are cell intrinsic to neurons. However, other glial cells in the CNS such as microglia and oligodendrocytes are also known to modulate learning and memory (Cornell et al., 2022; Steadman et al., 2020). Whether PERK signaling in microglia and oligodendrocytes can affect memory function still remains an open question. Consistent with previous reports (Shoji et al., 2016; Shoji & Miyakawa, 2019), we observed age-related decline in long-term memory. However, astrocytic PERK deletion did not exacerbate this cognitive decline.

Protein translation is also impacted by disease and neural injury. It has been known for several decades that transient cerebral ischemia, in both rodents and nonhuman primates, leads to suppression

of protein synthesis in the affected region (Cooper et al., 1977; Kleihues et al., 1975). These findings have been consistently reproduced by others that have shown that transient cerebral ischemia increases P-eIF2 α in a PERK-dependent fashion leading to suppression of protein synthesis (Althausen et al., 2001; Kumar et al., 2001; Mengesdorf et al., 2002; Owen et al., 2005; Sanderson et al., 2010). Targeting PERK by small-molecule inhibition was shown to attenuate MCAO-induced infarct volume (Li et al., 2019). In contrast, recent work has shown that deletion of PERK in neurons is detrimental following MCAO (Wang et al., 2020). Our data demonstrate that deletion of PERK from astrocytes also leads to worse outcome from experimental stroke. Together, these studies show that PERK signaling in both neurons and astrocytes is beneficial following experimental stroke. In this study, MCAO was conducted on mice that were over 18 months old. This is highly relevant as stroke primarily affects elderly individuals (Benjamin et al., 2019). Importantly, PERK was deleted for the life of the animal. Considering that, like neurons, astrocytes are long-lived cells (Sofroniew & Vinters, 2010) it is possible that disruption of PERK signaling sensitizes astrocytes to ischemic damage, but that short-term inhibition or deletion could be protective. Inducible deletion studies to allow temporal control of PERK deletion from astrocytes are underway to test this.

Another potential mechanism by which PERK deletion from astrocytes could be detrimental is through an impaired antioxidant response. The nuclear factor erythroid-2-related factor 2 (Nrf2) is a central regulator of the antioxidant response through driving expression of detoxifying enzymes and by promoting glutathione production (Ma, 2013). Nrf2 is activated following cerebral ischemia and has a protective role (Liu, Locascio, et al., 2019). Additionally, Nrf2 is activated in a PERK-dependent fashion during ER stress and the Nrf2 pathway has been shown to be protective in astrocytes (Cullinan et al., 2003; Gan et al., 2012; Vargas & Johnson, 2009). As such, deletion of PERK may impair Nrf2 activation in astrocytes following MCAO. Astrocytes have been shown to protect neurons through a variety of mechanisms including providing antioxidant defense (Baxter & Hardingham, 2016). This raises the possibility that PERK deletion may impair the astrocyte-mediated protection of neurons thus contributing to a worse outcome following MCAO.






FIGURE 3 Astrocytic PERK ablation does not alter long-term memory and cognitive flexibility in middle-aged mice. (a–c) Middle-aged (12 months) control and AstroPERK^{KO} ($n = 17$ for each genotype) mice were tested in the Morris water maze. Mice were trained to learn the hidden platform location for seven consecutive days. (a) Average latency (time) to find platform during the training phase is plotted for each genotype. Probe trials were administered right after the last training session. During probe trials, (b) percent time spent in individual quadrants and (c) time spent in platform area are plotted for each genotype. (d–f) The next day, the platform location was changed, and mice were retrained to learn the new platform position for two consecutive days (reversal training phase). (d) Average latency to find the platform during reversal training phase is plotted for each genotype. Reversal probe trials were conducted immediately after the last training session. (e) Percent time spent in individual quadrants and (f) time spent in platform are plotted for each genotype. Each point represents an individual animal (blue dot = male, orange dot = female). Numerical p values are shown. PTQ, target quadrant in previous probe trial; SE, southeast quadrant; NW, northwest quadrant; SW, southwest quadrant; TQ, target quadrant.

TABLE 5 Morris water maze test (Probe trial).

Age	12 months						18 months					
	Control			AstroPERK ^{KO}			Control			AstroPERK ^{KO}		
	M	F	N	M	F	N	M	F	N	M	F	N
N	6	9	6	5	9	6	3	5	3	5	4	
Total distance traveled (decimeter)	10.66±0.68	11.72±0.34	11.19±0.38	11.19±0.38	11.90±0.45	11.26±0.73	11.26±0.73	10.99±0.74	12.63±0.56	11.62±0.95	11.62±0.95	
Latency to first platform entry (seconds)	14.98±7.98	12.50±1.80	11.76±1.62	11.76±1.62	10.34±1.45	24.67±12.10	24.67±12.10	21.98±5.39	8.78±2.94	13.6±3.92	13.6±3.92	
Path efficiency to first platform entry	0.53±0.10	0.43±0.06	0.41±0.07	0.41±0.07	0.51±0.09	0.31±0.11	0.31±0.11	0.28±0.06	0.55±0.09	0.48±0.11	0.48±0.11	
Number of platform line crossing	3.67±0.81	4.11±0.55	5.20±0.59	5.20±0.59	5.11±0.94	3±0.94	3±0.94	1.8±0.33	5±0.8	2.75±0.65	2.75±0.65	
Time spent in platform area (seconds)	2.85±1.00	2.56±0.42	3.04±0.56	3.04±0.56	3.57±0.59	1.77±0.48	1.77±0.48	0.82±0.21	2.60±0.48	1.38±0.19	1.38±0.19	
Percent time spent in target (NE) quadrant	45.98±6.21	39.76±2.19	42.00±2.80	42.00±2.80	45.98±4.24	40.78±4.72	40.78±4.72	28.57±2.66	37.97±4.02	32.71±3.71	32.71±3.71	
Percent time spent in NW quadrant	22.17±5.51	23.63±2.16	28.43±4.16	28.43±4.16	29.69±2.40	28.50±1.65	28.50±1.65	22.70±2.95	26.57±2.66	24.63±3.67	24.63±3.67	
Percent time spent in SE quadrant	21.61±4.34	21.74±2.66	19.07±2.30	19.07±2.30	9.26±1.79	14.83±3.12	14.83±3.12	26.80±1.8	18.13±2.28	21.58±1.73	21.58±1.73	
Percent time spent in SW quadrant	10.56±1.70	14.83±1.47	10.53±0.87	10.53±0.87	15.07±2.90	15.94±3.04	15.94±3.04	21.93±0.87	17.30±2.54	20.96±1.03	20.96±1.03	

Note: Middle-aged (12 months) and old (18 months) control and AstroPERK^{KO} mice underwent Morris water maze test. Composite data from the probe trials are depicted in the table. Data are represented as Mean ± SEM.

Abbreviations: AstroPERK^{KO}, Astrocyte-specific PERK knockout mice; F, female; M, male; NE, Northeast quadrant; NW, Northwest quadrant; SE, Southeast quadrant; SW, Southwest quadrant; TQ, target quadrant.




FIGURE 4 Astrocytic PERK deletion does not alter long-term memory and cognitive flexibility in old mice. (a–c) Old (18 months) control ($n=8$), and AstroPERK^{KO} ($n=9$), mice were tested in the Morris water maze. Mice were trained to learn the hidden platform location for seven consecutive days. (a) Average latency to find platform during training phase is plotted for each genotype. Probe trials were administered right after the last training session. During the probe trials, (b) percent time spent in individual quadrants and (c) time spent in platform are plotted for each genotype. (d–f) The next day, the platform location was changed, and mice were retrained to learn the new platform position for two consecutive days (reversal training phase). (d) Average latency to find the platform during reversal training phase is plotted for each genotype. Reversal probe trials were conducted immediately after the completion of training. (e) Percent time spent in individual quadrants and (f) time spent in the platform area are plotted for each genotype. Each point represents an individual animal (blue dot = male, orange dot = female). Numerical p values are shown. NW, northwest quadrant; PTQ, target quadrant in previous probe trial; SE, southeast quadrant; SW, southwest quadrant; TQ, target quadrant.

TABLE 6 Morris water maze test (Reversal probe trial).

Age	12 months				18 months			
	Control		AstroPERK ^{KO}		Control		AstroPERK ^{KO}	
Genotype	Control		AstroPERK ^{KO}		Control		AstroPERK ^{KO}	
Sex	M	F	M	F	M	F	M	F
N	6	9	5	9	3	5	5	4
Total distance traveled (decimeter)	12.28±0.71	12.26±0.53	14.00±1.09	11.87±0.50	13.23±0.79	11.29±0.92	12.74±0.89	11.03±0.67
Latency to first platform entry (seconds)	11.55±2.51	15.30±2.22	8.70±2.80	22.26±4.57	14.37±1.38	28.27±7.76	12.90±3.7	18.43±3.72
Path efficiency to first platform entry	0.44±0.11	0.33±0.06	0.55±0.10	0.28±0.06	0.33±0.07	0.28±0.11	0.41±0.09	0.31±0.05
Number of platform line crossing	3.67±0.38	3.33±0.99	2.40±0.61	2.00±0.54	4±0.47	1.2±0.52	3.2±0.66	2.25±0.41
Time spent in platform area (seconds)	2.40±0.50	1.79±0.57	1.12±0.39	1.20±0.38	2.10±0.34	0.58±0.28	1.82±0.33	1.00±0.23
Percent time spent in NE (PT) quadrant	23.44±2.42	18.72±3.06	22.67±2.97	29.33±2.73	31.39±1.46	26.33±1.38	23.20±3.25	22.17±4.69
Percent time spent in NW quadrant	25.36±3.53	34.96±3.53	24.83±2.14	29.56±1.96	23.39±2.91	35.47±4.93	24.93±3.39	35.17±6.08
Percent time spent in SE quadrant	18.39±2.96	13.83±1.80	21.00±1.68	14.20±1.90	19.50±1.38	18.40±1.3	20.70±3.15	12.83±4.23
Percent time spent in target (SW) quadrant	32.72±4.31	32.50±4.50	31.47±3.13	26.87±2.57	25.83±1.73	19.83±4.48	31.17±4.15	29.75±3.92

Note: Middle-aged (12 months) and old (18 months) control and AstroPERK^{KO} mice underwent Morris water maze test. Composite data from the reversal probe trials are depicted in the table. Data are represented as Mean ± SEM.

Abbreviations: AstroPERK^{KO}, Astrocyte-specific PERK knockout mice; F, female; M, male; NE, Northeast quadrant; NW, Northwest quadrant; PTQ, previous target quadrant; SE, Southeast quadrant; SW, Southwest quadrant; TQ, target quadrant.




FIGURE 5 Astrocytic PERK ablation worsens experimental stroke outcome in old mice. Old (18 months; mean age = 550.1 days) control ($n = 11$) and AstroPERK^{KO} ($n = 13$) mice underwent MCAO. (a) Neuroscore was determined 24 h after the surgery and is plotted for each genotype. (b, c) Seventy-two hours after the surgery, mice underwent open field test. (b) Total ambulation and (c) total rearing activity are plotted for each genotype. (d) Percent survival until 72 h after the surgery is plotted for each genotype. Each point represents an individual animal (blue dot = male, orange dot = female). Numerical p values are shown.

UPR mediators, particularly PERK, have garnered attention recently as their activation has been reported in various rodent models of neurodegenerative disorders as well as in human patients

suffering from these ailments (Scheper & Hoozemans, 2015). Moreover, studies have also demonstrated that targeting eIF2 α phosphorylation can be a potential therapeutic approach in prion




FIGURE 6 Cerebral ischemia drives PERK-dependent CHOP expression in astrocytes. Tissue from a subset of animals shown in Figure 5 were used for immunostaining. (a) Representative images from contralateral and ipsilateral hemispheres stained from GFAP (white) and CHOP (orange). Scale bar = 50 μm. (b) Quantification of CHOP positive astrocytes (GFAP positive) and GFAP negative cells. Data are represented as means ± SD. Each point represents an individual animal. Numerical p values are shown.

disease and frontotemporal dementia (Halliday et al., 2015, 2017; Moreno et al., 2012, 2013; Radford et al., 2015). While there is great potential for modulation of PERK signaling as a therapeutic, there may be differential outcomes depending on the pathological condition. Our study, as well as others, have shown that targeting PERK can have detrimental consequences on CNS injury or disease (Athanasios et al., 2017; Lin et al., 2005; Shacham et al., 2021; Stone et al., 2019; Wang et al., 2020). However, targeting PERK in memory dysfunction remains promising. CNS activation of the UPR has been reported to significantly impair long-term spatial memory in multiple studies (Chen et al., 2021; Lin et al., 2018; Sun et al., 2017). In line with this, Sidrauski et al. demonstrated that reversing translational inhibition by administration of the small molecule ISRIB (integrated stress response inhibitor) enhanced long-term spatial memory (Sidrauski et al., 2013). Additionally, inhibition or knock-down of PERK boosted long-term memory and behavioral plasticity (Ounallah-Saad et al., 2014; Sharma et al., 2018). Forebrain-specific deletion of PERK using Camk2a-cre ameliorates memory decline in a model of Alzheimer's disease (Ma et al., 2013). In line with this finding, in vivo administration of soluble PERK inhibitor (GSK2656157) reverses traumatic brain injury (TBI)-induced memory decline and anxiety-like behavior (Sen et al., 2017, 2020). Poststroke cognitive impairment is common (Sun et al., 2014) and is potentially another condition that could benefit from pharmacological enhancement of translation initiation.

Genetic or pharmacological manipulation of proteostasis signaling pathways, particularly the unfolded protein response (UPR), can affect learning and memory deficits due to aging and neurological disorders (Cabral-Miranda et al., 2020; Ma et al., 2013; Sen et al., 2017). However, previous studies have focused on translational regulation in neurons and the contributions of these signaling events in nonneuronal cells in the context of cognitive function have not been well studied. Here, we have provided initial evidence that PERK signaling in astrocytes is more likely playing a role in the response to neural injury and has limited effects on cognitive function in normal unstressed condition. This is consistent with previous work showing that astrocytic PERK promotes neuroinflammation and neurodegeneration (Guthrie et al., 2016; Mearns et al., 2014; Smith et al., 2020). However, much remains unknown. Based on previous single-cell sequencing data, PERK is lowly expressed in astrocytes compared to other cells in the CNS (Saunders et al., 2018). Therefore, modulation of other eIF2α kinases in astrocytes may reveal a role in cognition. Similarly, other UPR mediators in astrocytes may have a role in cognition. IRE1α signaling in neurons has been implicated in long-term memory where genetic deletion of IRE1 and/or the downstream effector transcription factor XBP1 resulted in memory impairment (Cabral-Miranda et al., 2020; Martínez et al., 2016). Additionally, we deleted PERK in GFAP-expressing astrocytes, thus the role of PERK in non-GFAP astrocytes cannot be excluded. Astrocytic PERK is likely to influence






FIGURE 7 PERK does not regulate astrocyte number or morphology. Tissue from a subset of animals shown in Figure 5 were used for immunostaining. (a) GFAP⁺ astrocytes were quantified from two to three fields per animal from three mice of each genotype. Each point represents a microscopy field. (b) Branching degree (number of terminal branches/branches originating from the soma) was quantified and each data point represents an individual astrocyte. Dashed line and error bars represent geometric mean and SD. (c) Relative distribution of cells based on branching degree (graph is truncated when frequency reached <0.2%). (d) Feret diameter was quantified, and each data point represents an individual astrocyte. Dashed line and error bars represent geometric mean and SD. (e) Relative distribution of cells based on Feret diameter (graph is truncated when frequency reached <0.2%).

cognitive function in the context of neurological diseases through non-cell-autonomous effects on neurons, as previous work has shown that PERK signaling in astrocytes drives neurodegeneration in a mouse model of prion disease (Smith et al., 2020). If astrocytic PERK has a similar role in other neurological diseases remains to be determined. Future studies will likely show that, under pathological conditions, PERK signal in glial cells is multifaceted and can influence cognitive, inflammatory, and reparative processes.

AUTHOR CONTRIBUTIONS

Anirudhya Lahiri: conceptualization, data curation, formal analysis, project administration, investigation, writing - original draft; **James C. Walton:** conceptualization, methodology, writing - review & editing; **Ning Zhang:** investigation; **Neil Billington:** methodology, software, writing - review & editing; **A. Courtney DeVries:** conceptualization, writing - review & editing; **Gordon P. Meares:** conceptualization,

formal analysis, funding acquisition, project administration, supervision, writing - review & editing.

ACKNOWLEDGMENTS

We thank Dr. Elizabeth Chiurazzi and Ms. Terri Poling for helping in choosing appropriate behavioral test and analyses. We also thank Dr. Wen Zheng and Dr. Edwin Wan for assistance with cryosectioning, and Dr. Amanda Ammer for imaging. This work was supported by grants from the NIH (R01NS099304) (Stroke COBRE GM109098) (WVU CTSI U54GM104942). The WVU imaging facility is supported, in part, by grants from the NIH (U54GM104942 and P20GM103434). The WVU experimental stroke and behavioral core facilities are also supported by the NIH (GM109098).

CONFLICT OF INTEREST STATEMENT

The authors declare that they have no competing interests.



PEER REVIEW

The peer review history for this article is available at <https://www.webofscience.com/api/gateway/wos/peer-review/10.1002/jnr.25224>.

DATA AVAILABILITY STATEMENT

Data are available upon request.

ORCID

Anirudhya Lahiri  <https://orcid.org/0000-0002-8798-5484>

REFERENCES

- Adamsky, A., & Goshen, I. (2018). Astrocytes in memory function: Pioneering findings and future directions. *Neuroscience*, *370*, 14–26.
- Althausen, S., Mengesdorf, T., Mies, G., Oláh, L., Nairn, A. C., Proud, C. G., & Paschen, W. (2001). Changes in the phosphorylation of initiation factor eIF-2 α , elongation factor eEF-2 and p70 S6 kinase after transient focal cerebral ischaemia in mice. *Journal of Neurochemistry*, *78*, 779–787.
- Athanasiou, D., Aguila, M., Bellingham, J., Kanuga, N., Adamson, P., & Cheetham, M. E. (2017). The role of the ER stress-response protein PERK in rhodopsin retinitis pigmentosa. *Human Molecular Genetics*, *26*, 4896–4905.
- Baxter, P. S., & Hardingham, G. E. (2016). Adaptive regulation of the brain's antioxidant defences by neurons and astrocytes. *Free Radical Biology & Medicine*, *100*, 147–152.
- Ben Menachem-Zidon, O., Avital, A., Ben-Menahem, Y., Goshen, I., Kreisel, T., Shmueli, E. M., Segal, M., Ben Hur, T., & Yirmiya, R. (2011). Astrocytes support hippocampal-dependent memory and long-term potentiation via interleukin-1 signaling. *Brain, Behavior, and Immunity*, *25*, 1008–1016.
- Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., Delling, F. N., Djousse, L., Elkind, M. S. V., Ferguson, J. F., Fornage, M., Jordan, L. C., Khan, S. S., Kissela, B. M., Knutson, K. L., ... On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. (2019). Heart disease and stroke Statistics-2019 update: A report from the American Heart Association. *Circulation* *139*, e56–e528.
- Braakman, I., & Bulleid, N. J. (2011). Protein folding and modification in the mammalian endoplasmic reticulum. *Annual Review of Biochemistry*, *80*, 71–99.
- Brehme, M., Voisine, C., Rolland, T., Wachi, S., Soper, J. H., Zhu, Y., Orton, K., Vilella, A., Garza, D., Vidal, M., Ge, H., & Morimoto, R. I. (2014). A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. *Cell Reports*, *9*, 1135–1150.
- Brewer, J. W. (2014). Regulatory crosstalk within the mammalian unfolded protein response. *Cellular and Molecular Life Sciences*, *71*, 1067–1079.
- Cabral-Miranda, F., Tamburini, G., Martinez, G., Medinas, D., Gerakis, Y., Miedema, T., Duran-Aniotz, C., Ardiles, A. O., Gonzalez, C., Sabusap, C., Bermedo-Garcia, F., Adamson, S., Vitangcol, K., Huerta, H., Zhang, X., Nakamura, T., Sardi, S. P., Lipton, S. A., Kenedy, B. K., ... Hetz, C. (2020). Control of mammalian brain aging by the unfolded protein response (UPR). *bioRxiv*, 2020.2004.2013.039172.
- Chan, K. Y., Jang, M. J., Yoo, B. B., Greenbaum, A., Ravi, N., Wu, W. L., Sánchez-Guardado, L., Loiz, C., Mazmanian, S. K., Deverman, B. E., & Gradinaru, V. (2017). Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. *Nature Neuroscience*, *20*, 1172–1179.
- Chen, G., Wei, X., Xu, X., Yu, G., Yong, Z., Su, R., & Tao, L. (2021). Methamphetamine inhibits long-term memory acquisition and synaptic plasticity by evoking endoplasmic reticulum stress. *Frontiers in Neuroscience*, *14*, 1–10.
- Choleris, E., Thomas, A. W., Kavaliers, M., & Prato, F. S. (2001). A detailed ethological analysis of the mouse open field test: Effects of diazepam, chlordiazepoxide and an extremely low frequency pulsed magnetic field. *Neuroscience and Biobehavioral Reviews*, *25*, 235–260.
- Chou, A., Krukowski, K., Jopson, T., Zhu, P. J., Costa-Mattioli, M., Walter, P., & Rosi, S. (2017). Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury. *Proceedings of the National Academy of Sciences of the United States of America*, *114*, E6420–e6426.
- Citri, A., & Malenka, R. C. (2008). Synaptic plasticity: Multiple forms, functions, and mechanisms. *Neuropsychopharmacology*, *33*, 18–41.
- Cooper, H. K., Zalewska, T., Kawakami, S., Hossmann, K. A., & Kleihues, P. (1977). The effect of ischaemia and recirculation on protein synthesis in the rat brain. *Journal of Neurochemistry*, *28*, 929–934.
- Cornell, J., Salinas, S., Huang, H. Y., & Zhou, M. (2022). Microglia regulation of synaptic plasticity and learning and memory. *Neural Regeneration Research*, *17*, 705–716.
- Costa-Mattioli, M., Gobert, D., Harding, H., Herdy, B., Azzi, M., Bruno, M., Bidinosti, M., Ben Mamou, C., Marcinkiewicz, E., Yoshida, M., Imataka, H., Cuello, A. C., Seidah, N., Sossin, W., Lacaille, J. C., Ron, D., Nader, K., & Sonenberg, N. (2005). Translational control of hippocampal synaptic plasticity and memory by the eIF2 α kinase GCN2. *Nature*, *436*, 1166–1173.
- Costa-Mattioli, M., Gobert, D., Stern, E., Gamache, K., Colina, R., Cuello, C., Sossin, W., Kaufman, R., Pelletier, J., Rosenblum, K., Krnjević, K., Lacaille, J. C., Nader, K., & Sonenberg, N. (2007). eIF2 α phosphorylation bidirectionally regulates the switch from short- to long-term synaptic plasticity and memory. *Cell*, *129*, 195–206.
- Costa-Mattioli, M., Sossin, W. S., Klann, E., & Sonenberg, N. (2009). Translational control of long-lasting synaptic plasticity and memory. *Neuron*, *61*, 10–26.
- Costa-Mattioli, M., & Walter, P. (2020). The integrated stress response: From mechanism to disease. *Science*, *368*, eaat5314. <https://doi.org/10.1126/science.aat5314>
- Cullinan, S. B., Zhang, D., Hannink, M., Arvaisis, E., Kaufman, R. J., & Diehl, J. A. (2003). Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. *Molecular and Cellular Biology*, *23*, 7198–7209.
- Deary, I. J., Corley, J., Gow, A. J., Harris, S. E., Houlihan, L. M., Marioni, R. E., Penke, L., Rafnsson, S. B., & Starr, J. M. (2009). Age-associated cognitive decline. *British Medical Bulletin*, *92*, 135–152.
- Devi, L., & Ohno, M. (2014). PERK mediates eIF2 α phosphorylation responsible for BACE1 elevation, CREB dysfunction and neurodegeneration in a mouse model of Alzheimer's disease. *Neurobiology of Aging*, *35*, 2272–2281.
- Di Prisco, G. V., Huang, W., Buffington, S. A., Hsu, C. C., Bonnen, P. E., Placzek, A. N., Sidrauski, C., Krnjević, K., Kaufman, R. J., Walter, P., & Costa-Mattioli, M. (2014). Translational control of mGluR-dependent long-term depression and object-place learning by eIF2 α . *Nature Neuroscience*, *17*, 1073–1082.
- Gan, L., Vargas, M. R., Johnson, D. A., & Johnson, J. A. (2012). Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. *The Journal of Neuroscience*, *32*, 17775–17787.
- GBD 2016 Neurology Collaborators. (2019). Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the global burden of disease study 2016. *Lancet Neurology*, *18*, 459–480.
- Glassman, E. (1969). The biochemistry of learning: An evaluation of the role of RNA and protein. *Annual Review of Biochemistry*, *38*, 605–646.



- Gregorian, C., Nakashima, J., Le Belle, J., Ohab, J., Kim, R., Liu, A., Smith, K. B., Groszer, M., Garcia, A. D., Sofroniew, M. V., Carmichael, S. T., Kornblum, H. I., Liu, X., & Wu, H. (2009). Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. *The Journal of Neuroscience*, *29*, 1874–1886.
- Guthrie, L. N., Abiraman, K., Plyler, E. S., Sprenkle, N. T., Gibson, S. A., McFarland, B. C., Rajbhandari, R., Rowse, A. L., Benveniste, E. N., & Meares, G. P. (2016). Attenuation of PKR-like ER kinase (PERK) signaling selectively controls endoplasmic reticulum stress-induced inflammation without compromising immunological responses. *The Journal of Biological Chemistry*, *291*, 15830–15840.
- Halliday, M., Radford, H., Sekine, Y., Moreno, J., Verity, N., le Quesne, J., Ortori, C. A., Barrett, D. A., Fromont, C., Fischer, P. M., Harding, H. P., Ron, D., & Mallucci, G. R. (2015). Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. *Cell Death & Disease*, *6*, e1672.
- Halliday, M., Radford, H., Zents, K. A. M., Molloy, C., Moreno, J. A., Verity, N. C., Smith, E., Ortori, C. A., Barrett, D. A., Bushell, M., & Mallucci, G. R. (2017). Repurposed drugs targeting eIF2 α -P-mediated translational repression prevent neurodegeneration in mice. *Brain*, *140*, 1768–1783.
- Han, J., Kesner, P., Metna-Laurent, M., Duan, T., Xu, L., Georges, F., Koehl, M., Abrous, D. N., Mendizabal-Zubiaga, J., Grandes, P., Liu, Q., Bai, G., Wang, W., Xiong, L., Ren, W., Marsicano, G., & Zhang, X. (2012). Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. *Cell*, *148*, 1039–1050.
- Harding, H. P., Zhang, Y., & Ron, D. (1999). Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. *Nature*, *397*, 271–274.
- Harding, H. P., Zhang, Y., Zeng, H., Novoa, I., Lu, P. D., Calton, M., Sadri, N., Yun, C., Popko, B., Paules, R., Stojdl, D. F., Bell, J. C., Hettmann, T., Leiden, J. M., & Ron, D. (2003). An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. *Molecular Cell*, *11*, 619–633.
- Hattori, K., Lee, H., Hurn, P. D., Crain, B. J., Traystman, R. J., & DeVries, A. C. (2000). Cognitive deficits after focal cerebral ischemia in mice. *Stroke; a Journal of Cerebral Circulation*, *31*, 1939–1944.
- Hetz, C., & Mollereau, B. (2014). Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. *Nature Reviews Neuroscience*, *15*, 233–249.
- Hipp, M. S., Kasturi, P., & Hartl, F. U. (2019). The proteostasis network and its decline in ageing. *Nature Reviews Molecular Cell Biology*, *20*, 421–435.
- Kennard, J. A., & Woodruff-Pak, D. S. (2011). Age sensitivity of behavioral tests and brain substrates of normal aging in mice. *Frontiers in Aging Neuroscience*, *3*, 9.
- Klann, E., & Sweatt, J. D. (2008). Altered protein synthesis is a trigger for long-term memory formation. *Neurobiology of Learning and Memory*, *89*, 247–259.
- Kleihues, P., Hossmann, K. A., Pegg, A. E., Kobayashi, K., & Zimmermann, V. (1975). Resuscitation of the monkey brain after one hour complete ischemia. III. Indications of metabolic recovery. *Brain Research*, *95*, 61–73.
- Krishnamoorthy, T., Pavitt, G. D., Zhang, F., Dever, T. E., & Hinnebusch, A. G. (2001). Tight binding of the phosphorylated alpha subunit of initiation factor 2 (eIF2 α) to the regulatory subunits of guanine nucleotide exchange factor eIF2B is required for inhibition of translation initiation. *Molecular and Cellular Biology*, *21*, 5018–5030.
- Kumar, R., Azam, S., Sullivan, J. M., Owen, C., Cavener, D. R., Zhang, P., Ron, D., Harding, H. P., Chen, J. J., Han, A., White, B. C., Krause, G. S., & DeGracia, D. J. (2001). Brain ischemia and reperfusion activates the eukaryotic initiation factor 2 α kinase, PERK. *Journal of Neurochemistry*, *77*, 1418–1421.
- Labbadia, J., & Morimoto, R. I. (2015). The biology of proteostasis in aging and disease. *Annual Review of Biochemistry*, *84*, 435–464.
- Li, M., Su, S., Cai, W., Cao, J., Miao, X., Zang, W., Gao, S., Xu, Y., Yang, J., Tao, Y. X., & Ai, Y. (2020). Differentially expressed genes in the brain of aging mice with cognitive alteration and depression- and anxiety-like behaviors. *Frontiers in Cell and Development Biology*, *8*, 814.
- Li, Y., Zhang, Y., Fu, H., Huang, H., Lu, Q., Qin, H., Wu, Y., Huang, H., Mao, G., Wei, Z., & Liao, P. (2019). Hes1 knockdown exacerbates ischemic stroke following tMCAO by increasing ER stress-dependent apoptosis via the PERK/eIF2 α /ATF4/CHOP signaling pathway. *Neuroscience Bulletin*, *36*, 134–142.
- Lin, L., Cao, J., Yang, S. S., Fu, Z. Q., Zeng, P., Chu, J., Ning, L. N., Zhang, T., Shi, Y., Tian, Q., Zhou, X. W., & Wang, J. Z. (2018). Endoplasmic reticulum stress induces spatial memory deficits by activating GSK-3. *Journal of Cellular and Molecular Medicine*, *22*, 3489–3502.
- Lin, W., Harding, H. P., Ron, D., & Popko, B. (2005). Endoplasmic reticulum stress modulates the response of myelinating oligodendrocytes to the immune cytokine interferon-gamma. *The Journal of Cell Biology*, *169*, 603–612.
- Liu, C. Y., Schröder, M., & Kaufman, R. J. (2000). Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. *The Journal of Biological Chemistry*, *275*, 24881–24885.
- Liu, L., Locascio, L. M., & Doré, S. (2019). Critical role of Nrf2 in experimental ischemic stroke. *Frontiers in Pharmacology*, *10*, 153.
- Liu, Q., Johnson, E. M., Lam, R. K., Wang, Q., Bo Ye, H., Wilson, E. N., Minhas, P. S., Liu, L., Swarovski, M. S., Tran, S., Wang, J., Mehta, S. S., Yang, X., Rabinowitz, J. D., Yang, S. S., Shamloo, M., Mueller, C., James, M. L., & Andreasson, K. I. (2019). Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity. *Nature Immunology*, *20*, 1023–1034.
- Longa, E. Z., Weinstein, P. R., Carlson, S., & Cummins, R. (1989). Reversible middle cerebral artery occlusion without craniectomy in rats. *Stroke; A Journal of Cerebral Circulation*, *20*, 84–91.
- López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. *Cell*, *153*, 1194–1217.
- Ma, Q. (2013). Role of nrf2 in oxidative stress and toxicity. *Annual Review of Pharmacology and Toxicology*, *53*, 401–426.
- Ma, T., Trinh, M. A., Wexler, A. J., Bourbon, C., Gatti, E., Pierre, P., Cavener, D. R., & Klann, E. (2013). Suppression of eIF2 α kinases alleviates Alzheimer's disease-related plasticity and memory deficits. *Nature Neuroscience*, *16*, 1299–1305.
- Martínez, G., Duran-Aniotz, C., Cabral-Miranda, F., Vivar, J. P., & Hetz, C. (2017). Endoplasmic reticulum proteostasis impairment in aging. *Aging Cell*, *16*, 615–623.
- Martínez, G., Vidal, R. L., Mardones, P., Serrano, F. G., Ardiles, A. O., Wirth, C., Valdés, P., Thielen, P., Schneider, B. L., Kerr, B., Valdés, J. L., Palacios, A. G., Inestrosa, N. C., Glimcher, L. H., & Hetz, C. (2016). Regulation of memory formation by the transcription factor XBP1. *Cell Reports*, *14*, 1382–1394.
- Meares, G. P., Liu, Y., Rajbhandari, R., Qin, H., Nozell, S. E., Mobley, J. A., Corbett, J. A., & Benveniste, E. N. (2014). PERK-dependent activation of JAK1 and STAT3 contributes to endoplasmic reticulum stress-induced inflammation. *Molecular and Cellular Biology*, *34*, 3911–3925.
- Meares, G. P., Ma, X., Qin, H., & Benveniste, E. N. (2012). Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. *Glia*, *60*, 771–781.
- Mengesdorf, T., Proud, C. G., Mies, G., & Paschen, W. (2002). Mechanisms underlying suppression of protein synthesis induced by transient focal cerebral ischemia in mouse brain. *Experimental Neurology*, *177*, 538–546.
- Moreno, J. A., Halliday, M., Molloy, C., Radford, H., Verity, N., Axten, J. M., Ortori, C. A., Willis, A. E., Fischer, P. M., Barrett, D. A., & Mallucci, G. R. (2013). Oral treatment targeting the unfolded protein response

- prevents neurodegeneration and clinical disease in prion-infected mice. *Science Translational Medicine*, 5, 206ra138.
- Moreno, J. A., Radford, H., Peretti, D., Steinert, J. R., Verity, N., Martin, M. G., Halliday, M., Morgan, J., Dinsdale, D., Ortori, C. A., Barrett, D. A., Tsaytler, P., Bertolotti, A., Willis, A. E., Bushell, M., & Mallucci, G. R. (2012). Sustained translational repression by eIF2 α -P mediates prion neurodegeneration. *Nature*, 485, 507–511.
- Morimoto, N., Oida, Y., Shimazawa, M., Miura, M., Kudo, T., Imaizumi, K., & Hara, H. (2007). Involvement of endoplasmic reticulum stress after middle cerebral artery occlusion in mice. *Neuroscience*, 147, 957–967.
- Oliveira, M. M., & Klann, E. (2022). eIF2-dependent translation initiation: Memory consolidation and disruption in Alzheimer's disease. *Seminars in Cell & Developmental Biology*, 125, 101–109.
- Oliveira, M. M., Lourenco, M. V., Longo, F., Kasica, N. P., Yang, W., Ureta, G., Ferreira, D. D. P., Mendonça, P. H. J., Bernales, S., Ma, T., De Felice, F. G., Klann, E., & Ferreira, S. T. (2021). Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer's disease. *Science Signaling*, 14, eabc5429.
- Ota, Y., Zanetti, A. T., & Hallock, R. M. (2013). The role of astrocytes in the regulation of synaptic plasticity and memory formation. *Neural Plasticity*, 2013, 185463.
- Ounallah-Saad, H., Sharma, V., Edry, E., & Rosenblum, K. (2014). Genetic or pharmacological reduction of PERK enhances cortical-dependent taste learning. *The Journal of Neuroscience*, 34, 14624–14632.
- Owen, C. R., Kumar, R., Zhang, P., McGrath, B. C., Cavener, D. R., & Krause, G. S. (2005). PERK is responsible for the increased phosphorylation of eIF2 α and the severe inhibition of protein synthesis after transient global brain ischemia. *Journal of Neurochemistry*, 94, 1235–1242.
- Paz Gavilán, M., Vela, J., Castaño, A., Ramos, B., del Río, J. C., Vitorica, J., & Ruano, D. (2006). Cellular environment facilitates protein accumulation in aged rat hippocampus. *Neurobiology of Aging*, 27, 973–982.
- Prieur, E. A. K., & Jadavji, N. M. (2019). Assessing spatial working memory using the spontaneous alternation Y-maze test in aged male mice. *Bio-Protocol*, 9, e3162.
- Radford, H., Moreno, J. A., Verity, N., Halliday, M., & Mallucci, G. R. (2015). PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. *Acta Neuropathologica*, 130, 633–642.
- Rissanen, A., Sivenius, J., & Jolkkonen, J. (2006). Prolonged bihemispheric alterations in unfolded protein response related gene expression after experimental stroke. *Brain Research*, 1087, 60–66.
- Ron, D., & Harding, H. P. (2000). PERK and translational control by stress in the endoplasmic reticulum. In N. Sonenberg, J. W. B. Hershey, & M. B. Mathews (Eds.), *Translational control of gene expression* (pp. 547–560). New York: Cold Spring Harbor Laboratory Press.
- Ron, D., & Walter, P. (2007). Signal integration in the endoplasmic reticulum unfolded protein response. *Nature Reviews. Molecular Cell Biology*, 8, 519–529.
- Sanderson, T. H., Deogracias, M. P., Nangia, K. K., Wang, J., Krause, G. S., & Kumar, R. (2010). PKR-like endoplasmic reticulum kinase (PERK) activation following brain ischemia is independent of unfolded nascent proteins. *Neuroscience*, 169, 1307–1314.
- Saunders, A., Macosko, E. Z., Wysoker, A., Goldman, M., Krienen, F. M., de Rivera, H., Bien, E., Baum, M., Bortolin, L., Wang, S., Goeva, A., Nemesh, J., Kamitaki, N., Brumbaugh, S., Kulp, D., & McCarroll, S. A. (2018). Molecular diversity and specializations among the cells of the adult mouse brain. *Cell*, 174, 1015–1030.e1016.
- Scheper, W., & Hoozemans, J. J. (2015). The unfolded protein response in neurodegenerative diseases: A neuropathological perspective. *Acta Neuropathologica*, 130, 315–331.
- Schwarz, D. S., & Blower, M. D. (2016). The endoplasmic reticulum: Structure, function and response to cellular signaling. *Cellular and Molecular Life Sciences*, 73, 79–94.
- Sen, T., Gupta, R., Kaiser, H., & Sen, N. (2017). Activation of PERK elicits memory impairment through inactivation of CREB and down-regulation of PSD95 after traumatic brain injury. *The Journal of Neuroscience*, 37, 5900–5911.
- Sen, T., Saha, P., Gupta, R., Foley, L. M., Jiang, T., Abakumova, O. S., Hitchens, T. K., & Sen, N. (2020). Aberrant ER stress induced neuronal-IFN β elicits White matter injury due to microglial activation and T-cell infiltration after TBI. *The Journal of Neuroscience*, 40, 424–446.
- Shacham, T., Patel, C., & Lederkremer, G. Z. (2021). PERK pathway and neurodegenerative disease: To inhibit or to activate? *Biomolecules*, 11, 354. <https://doi.org/10.3390/biom11030354>
- Sharma, V., Ounallah-Saad, H., Chakraborty, D., Hleihil, M., Sood, R., Barrera, I., Edry, E., Kolatt Chandran, S., Tabou, B., de Leon, S., Kaphzan, H., & Rosenblum, K. (2018). Local inhibition of PERK enhances memory and reverses age-related deterioration of cognitive and neuronal properties. *The Journal of Neuroscience*, 38, 648–658.
- Shoji, H., & Miyakawa, T. (2019). Age-related behavioral changes from young to old age in male mice of a C57BL/6J strain maintained under a genetic stability program. *Neuropsychopharmacol Rep*, 39, 100–118.
- Shoji, H., Takao, K., Hattori, S., & Miyakawa, T. (2016). Age-related changes in behavior in C57BL/6J mice from young adulthood to middle age. *Molecular Brain*, 9, 11.
- Sidrauski, C., Acosta-Alvear, D., Khoutorsky, A., Vedantham, P., Hearn, B. R., Li, H., Gamache, K., Gallagher, C. M., Ang, K. K., Wilson, C., Okreglak, V., Ashkenazi, A., Hann, B., Nader, K., Arkin, M. R., Renso, A. R., Sonenberg, N., & Walter, P. (2013). Pharmacological brake-release of mRNA translation enhances cognitive memory. *eLife*, 2, e00498.
- Smith, H. L., Freeman, O. J., Butcher, A. J., Holmqvist, S., Humoud, I., Schätzl, T., Hughes, D. T., Verity, N. C., Swinden, D. P., Hayes, J., de Weerd, L., Rowitch, D. H., Franklin, R. J. M., & Mallucci, G. R. (2020). Astrocyte unfolded protein response induces a specific reactivity state that causes non-cell-autonomous neuronal degeneration. *Neuron*, 105, 855–866.e855.
- Sofroniew, M. V. (2009). Molecular dissection of reactive astrogliosis and glial scar formation. *Trends in Neurosciences*, 32, 638–647.
- Sofroniew, M. V., & Vinters, H. V. (2010). Astrocytes: Biology and pathology. *Acta Neuropathologica*, 119, 7–35.
- Sprenkle, N. T., Sims, S. G., Sánchez, C. L., & Meares, G. P. (2017). Endoplasmic reticulum stress and inflammation in the central nervous system. *Molecular Neurodegeneration*, 12, 42.
- Steadman, P. E., Xia, F., Ahmed, M., Mocle, A. J., Penning, A. R. A., Geraghty, A. C., Steenland, H. W., Monje, M., Josselyn, S. A., & Frankland, P. W. (2020). Disruption of Oligodendrogenesis impairs memory consolidation in adult mice. *Neuron*, 105, 150–164.e156.
- Stehberg, J., Moraga-Amaro, R., Salazar, C., Becerra, A., Echeverría, C., Orellana, J. A., Bultynck, G., Ponsaerts, R., Leybaert, L., Simon, F., Sáez, J. C., & Retamal, M. A. (2012). Release of gliotransmitters through astroglial connexin 43 hemichannels is necessary for fear memory consolidation in the basolateral amygdala. *The FASEB Journal*, 26, 3649–3657.
- Stirling, D. R., Swain-Bowden, M. J., Lucas, A. M., Carpenter, A. E., Cimini, B. A., & Goodman, A. (2021). CellProfiler 4: Improvements in speed, utility and usability. *BMC Bioinformatics*, 22, 433.
- Stone, S., Yue, Y., Stanojlovic, M., Wu, S., Karsenty, G., & Lin, W. (2019). Neuron-specific PERK inactivation exacerbates neurodegeneration during experimental autoimmune encephalomyelitis. *JCI Insight*, 4, 1–17.
- Sun, H., Yang, Y., Shao, H., Sun, W., Gu, M., Wang, H., Jiang, L., Qu, L., Sun, D., & Gao, Y. (2017). Sodium Arsenite-induced learning and memory impairment is associated with endoplasmic reticulum stress-mediated apoptosis in rat hippocampus. *Frontiers in Molecular Neuroscience*, 10, 1–14.
- Sun, J. H., Tan, L., & Yu, J. T. (2014). Post-stroke cognitive impairment: Epidemiology, mechanisms and management. *Annals of Translational Medicine*, 2, 80.



- Suzuki, A., Stern, S. A., Bozdagi, O., Huntley, G. W., Walker, R. H., Magistretti, P. J., & Alberini, C. M. (2011). Astrocyte-neuron lactate transport is required for long-term memory formation. *Cell*, *144*, 810–823.
- Taylor, R. C. (2016). Aging and the UPR(ER). *Brain Research*, *1648*, 588–593.
- Trinh, M. A., Kaphzan, H., Wek, R. C., Pierre, P., Cavener, D. R., & Klann, E. (2012). Brain-specific disruption of the eIF2 α kinase PERK decreases ATF4 expression and impairs behavioral flexibility. *Cell Reports*, *1*, 676–688.
- Trinh, M. A., & Klann, E. (2013). Translational control by eIF2 α kinases in long-lasting synaptic plasticity and long-term memory. *Neurobiology of Learning and Memory*, *105*, 93–99.
- van Praag, H., Shubert, T., Zhao, C., & Gage, F. H. (2005). Exercise enhances learning and hippocampal neurogenesis in aged mice. *The Journal of Neuroscience*, *25*, 8680–8685.
- Vargas, M. R., & Johnson, J. A. (2009). The Nrf2-ARE cytoprotective pathway in astrocytes. *Expert Reviews in Molecular Medicine*, *11*, e17.
- Vorhees, C. V., & Williams, M. T. (2006). Morris water maze: Procedures for assessing spatial and related forms of learning and memory. *Nature Protocols*, *1*, 848–858.
- Walter, P., & Ron, D. (2011). The unfolded protein response: From stress pathway to homeostatic regulation. *Science*, *334*, 1081–1086.
- Wang, Y. C., Li, X., Shen, Y., Lyu, J., Sheng, H., Paschen, W., & Yang, W. (2020). PERK (protein kinase RNA-like ER kinase) branch of the unfolded protein response confers neuroprotection in ischemic stroke by suppressing protein synthesis. *Stroke; A Journal of Cerebral Circulation*, *51*, 1570–1577.
- Wyss-Coray, T. (2016). Ageing, neurodegeneration and brain rejuvenation. *Nature*, *539*, 180–186.
- Zhang, K., & Kaufman, R. J. (2008). From endoplasmic-reticulum stress to the inflammatory response. *Nature*, *454*, 455–462.
- Zhang, P., McGrath, B., Li, S., Frank, A., Zambito, F., Reinert, J., Gannon, M., Ma, K., McNaughton, K., & Cavener, D. R. (2002). The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. *Molecular and Cellular Biology*, *22*, 3864–3874.
- Zhu, S., Henninger, K., McGrath, B. C., & Cavener, D. R. (2016). PERK regulates working memory and protein synthesis-dependent memory flexibility. *PLoS One*, *11*, e0162766.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

Supplementary Figure 1: Age alters long-term memory. (a–c) During the probe trials, (a) percent time spent in target quadrant, (b) time spent in platform area, and (c) number of platform line crossings are plotted for the middle-aged and old mice, respectively. (d–f) During the reversal probe trials, (d) percent time in target quadrant, (e) time spent in platform area, and (f) number of platform line crossings are plotted for both age groups, respectively. Each point represents an individual animal (blue dot = male, orange dot = female). Numerical p values are shown.

Supplementary Figure 2: MCAO-induced infarction. At 72 h post-MCAO, the surviving animals shown in Figure 5 were euthanized and brains were stained with TTC. Images of each animal are shown. The space between the dashes on the top and right of the images is 1 mm.

Supplementary Figure 3: Histopathology. Representative H&E images from cortex, striatum, and hippocampal CA1 region of control and AstroPERK^{KO} mice 72 h post-MCAO. Contralateral and ipsilateral sections are shown. Inset indicates location of enlarged image.

How to cite this article: Lahiri, A., Walton, J. C., Zhang, N., Billington, N., DeVries, A. C., & Meares, G. P. (2023). Astrocytic deletion of protein kinase R-like ER kinase (PERK) does not affect learning and memory in aged mice but worsens outcome from experimental stroke. *Journal of Neuroscience Research*, *101*, 1586–1610. <https://doi.org/10.1002/jnr.25224>

